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ABSTRACT 
 
Weihua Song 
Human Nav1.5 F1486 deletion associated with long-QT syndrome leads to 
deficiency in inactivation and reduces lidocaine sensitivity 
The cardiac voltage-gated sodium channel α subunit Nav1.5 generates 
the cardiac sodium current, which is essential for the initiation and propagation of 
the cardiac action potentials. Mutations of SCN5A, the gene that encodes Nav1.5, 
have been well documented to cause long-QT syndrome (LQTs) by disrupting 
channel inactivation and increasing late sodium current. Previous studies have 
revealed the importance of the intracellular loop region between transmembrane 
domain III and IV of sodium channel α subunit in regulating the fast inactivation. A 
recent clinical case study reported an infant patient with LQTs carrying a 
phenylalanine (F) deletion at amino acid 1486 of the Nav1.5 channel. This study 
reported that the patient showed severe cardiac arrhythmia reflected as LQTs 
and subsequent ventricular tachycardia, which was refractory to antiarrhythmic 
drug lidocaine treatment. Therefore, it was hypothesized that the deletion of 
F1486 on Nav1.5 would substantially alter electrophysiological properties of the 
channel and reduce the potency of lidocaine on sodium channel. Using HEK293 
cells and neonatal rat cardiomyocytes, the F1486del channel was functionally 
characterized by whole-cell patch-clamp techniques. Studies revealed that the 
deletion of F1486 causes a combination of changes including a loss-of-function 
alteration reflected as a substantial reduction of peak current density and a 
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number of gain-of-function alterations including reduced channel inactivation, 
substantial augmentation of late sodium current, and an increase in ramp current. 
In addition, lidocaine sensitivity was dramatically reduced. By contrast, the 
voltage for half maximal activation (V1/2) and the time constant for channel 
deactivation for the F1486del channel were identical to the wild type channels. 
Using neonatal rat cardiomyocytes, we were able to study the functional 
consequence of F1484del on action potential duration (APD). Cardiomyocytes 
expressing F1486del channel have substantial APD prolongation and prominent 
spontaneous early afterdepolarizations, which likely underlie the subsequent 
LQTs in the patient. Taken together, despite the reduction in peak current density, 
the substantial gain-of-function changes are sufficient to cause the APD 
prolongation, which is a prominent characteristic of LQTs. These findings provide 
knowledge for understanding the relationships between sodium channel structure, 
pharmacology and the physiological consequence of sodium channel mutations 
that underlie LQT3. 
 
Weinian Shou, Ph.D., Chair 
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I. INTRODUCTION 
 
A. Overview of the thesis Project 
Inherited long-QT syndrome (LQTs) is an infrequent but serious medical 
problem of the heart’s rhythm. It usually affects children and young adults. 
Patients with LQTs who have symptoms often exhibit syncope and cardiac 
arrhythmia, which potentially could cause sudden death. Genetic mutation of the 
gene SCN5A encoding human voltage-gated cardiac sodium channel hNav1.5 
can put patients at risk of type 3 LQT syndrome (LQT3), a type of cardiac 
arrhythmia that is typically associated with a gain-of-function mutation in the 
cardiac sodium channel.  
Nav1.5 is the predominant form of sodium channel that expresses in the 
heart. Over the last twenty years, numerous studies have investigated the role of 
Nav1.5 channels in cardiac arrhythmia, especially LQT3. The vast majority of 
studies have focused on the biophysical properties of Nav1.5 sodium channel 
carrying specific polymorphisms associated with LQT3. There is overwhelming 
evidence suggesting that LQT3 might be predominantly caused by sodium 
channel gain-of-function mutations. Although the potential outcome of this 
disease can be lethal, it is a treatable disease. In general, there are treatments 
for LQTs, including medications such as β blockers that block sodium current in a 
manner similar to the blocking by local anesthetics (Bankston & Kass, 2010). 
Sometimes, a surgical procedure can be performed, and some patients may 
benefit from an implantable defibrillator. Treatment for LQT3 includes therapeutic 
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drugs such as Mexiletine, a sodium channel blocker, which is predicted to be 
especially effective when other drugs fail. As a long-term goal, it is of importance 
to reveal effective drugs for specific sodium channel mutations, which is now 
called “mutation/gene-specific approach” (An et al., 1998; Benhorin et al., 2000) .  
Previous studies on the neuronal sodium channel Nav1.2 indicated that 
the intracellular loop III between transmembrane domain III and IV is critical for 
sodium channel fast inactivation (West et al., 1992). Using a mutagenesis 
approach, West et al. have demonstrated the essential role of a three amino acid 
residue cluster IFM in channel fast inactivation. Nonetheless, these works on the 
electrophysiology properties of the sodium channels were carried out mostly 
using the heterologous expression systems such as Chinese Hamster Ovary 
cells and Xenopus oocytes. In addition, it is not clear whether these amino acids 
work in the cardiac sodium channel Nav1.5 through the same mechanism. 
This thesis is mainly focused on the biophysical and pharmacological 
properties of the human cardiac sodium channel Nav1.5 carrying the 
phenylalanine (Phe, F) deletion at amino acid F1486, an intriguing site that is 
believed to be critical for channel inactivation (West et al., 1992). Based on the 
data collected from both HEK293 cells and primary cultured neonatal rat 
cardiomyocytes, this thesis provides strong evidence indicating that the F1486del 
disrupts sodium channel inactivation and increases late sodium current. Like 
other LQT3-associated mutations, the F1486del leads to a series of sodium 
channel gain-of-function alterations. Surprisingly, F486del causes decreased 
current density in both cell types, indicating a loss-of-function alteration. Action 
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potential duration prolongation and the prominent early afterdepolarizations were 
observed in cultured ventricular cardiomyocytes, which underline the mechanism 
of long-QT syndrome and the subsequent ventricular tachycardia in the newborn 
patient. More importantly, this thesis revealed the mechanism for the refractory 
response of the patient to antiarrhythmic drug lidocaine. This particular finding 
provides strong evidence supporting the idea that certain mutations can alter the 
channel’s response to antiarrhythmic drugs. Thus, it is of great importance to 
identify the effective drugs that can be used for mutation specific individualized 
therapy in the future.  
B. Basic methodology used in studying the function of VGSCs: 
patch-clamp techniques 
So far, the most direct way of investigating ion channel function is to 
record the current that flows through the channel across the cell membrane, or, 
to measure the membrane potential changes that the current produces. The 
profound advance in electrophysiology came with the development of patch-
clamp methods. This technique was invented by Erwin Neher and Bert Sakmann, 
who were awarded with the Nobel Prize in “Physiology or Medicine” in 1991 for 
their discoveries concerning the function of single ion channels in cells. In 1976, 
Neher and Sakmann first tried to record current from a tiny area of cell surface 
membrane (so called “patch”) by pressing a heat-polished pipette against a living 
cell. The first evidence of the success of this technique was published in the 
paper by Neher and Sakmann in 1976 (Neher & Sakmann, 1976). In 1981, 
another breakthrough was made by them when the clean glass pipette can fuse 
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to the cell membrane to form a seal resistance called gigaseal (109) in 
comparison with the conventional seal level of mega ohm. The high resistance of 
this seal ensures that most of the currents originating in a small patch of 
membrane flow into the pipette, and from there into the current-measurement 
circuitry. The level of seal resistance is critical also because it determines the 
level of background noise in recordings.  
Four recording configurations can be formed based on the high seal 
resistance (Figure 1): 1) On-cell or cell-attached mode: this configuration can be 
achieved as soon as the pipette is sealed to the cell membrane with a high level 
of resistance of gigaseal. Under this recording mode, single channel recordings 
can be obtained. 2) Inside-out or excised-patch mode: this configuration is 
achieved by getting a stable high seal resistance first, and then pulling off the cell 
that is still tightly sealed to the pipette. By bathing the pulled-off part in the 
bathing solution, the functional changes can be studied specifically in the inside 
part (intracellular cytosolic side) of the cell membrane (ion channels) by replacing 
the component in the bathing solution. 3) Whole-cell configuration: this mode is 
achieved by deliberately rupturing the on-cell patch by gentle suction without 
disrupting the seal. After the whole-cell configuration is made, the pipette solution 
will diffuse into the cell cytoplasm and the composition of these two solutions will 
exchange and finally reach equilibrium within a few minutes. Typically, the 
functions of ion channels have been studied using this configuration. Since the 
pipette solution exchanges molecules with the cytoplasmic component under the 
whole-cell configuration, this configuration has become a useful tool to deliver 
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metabolites, inhibitors of signal transduction pathways, or fluorescent dyes during 
the recordings. 4) Out-side out patch mode: this configuration is formed by 
pulling the pipette away from the cell in whole-cell mode making the cytoplasmic 
face of the outer membrane of the cell being exposed to the pipette solution, and 
its extracellular face to the bath solution. By varying the composition of the bath 
solution, the effect of drug or ion concentration changes on currents can be 
investigated at either the cytoplasmic or the extracellular face of the membrane. 
In my thesis work, all of the sodium channel recordings were made using 
whole-cell configuration. 
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Figure 1. Illustration of four gigaseal recording methods. This figure was 
modified from Hamill et al, 1981; Pflügers Arch 391, 85-100 and Hille B, 1992 
Sinauer Associates Inc.. The cell configuration used in this thesis work is solely 
whole-cell configuration. 
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C. Background information of VGSCs: research history, structure, function,  
and modulation 
Sodium channels are integral membrane proteins. In general, sodium 
channel can be classified into two categories: one category is the sodium 
channels that are not voltage-gated; the epithelial sodium channel 
(EnaC)/degenerin (DEG) gene family that mediate sodium transport in epithelial 
and other cell types (Palmer & Frindt, 1986; Roudier-Pujol et al., 1996; 
Kellenberger & Schild, 2002). The other is voltage-gated sodium channels 
(VGSCs), with the characteristic of altering the gating kinetics in response to the 
membrane voltage changes. The epithelial sodium channel is structurally 
unrelated to the voltage-gated sodium channel. In the following context, the term 
“sodium channel” will be solely used to refer to the “voltage-gated sodium 
channel”. 
As the first member of the ion channel super family that has been 
discovered, the function of sodium channel was discovered by Hodgkin and 
Huxley in 1952. The other member that was very first uncovered in the early 
years was the potassium channel. Voltage-gated Ca2+ channel was recognized 
almost a decade later. Using squid axons, Hodgkin and Huxley observed 
transient inward and sustained outward currents that they believe to carry 
enough charges to contribute to the rapid rise and fall of the action potential. With 
the help of the early stage voltage-clamp technique, Hodgkin and Huxley 
advanced the conceptual knowledge of ionic currents. They identified two major 
components of the membrane current: INa and IK (Hodgkin & Huxley, 1952a; 
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Hodgkin, 1958; Hille, 2001). By replacing the external solution with choline 
chloride, Hodgkin and Huxley confirmed the early transient component in the 
ionic current as the INa, since removal of the external Na
+ could completely 
abolish this current (Hille, 2001). Several years after Hodgkin and Huxley’s work, 
the formal terminology immerges for the axon ion channel description: “sodium 
channels” which have a positive reversal potential, ENa, and “potassium channels” 
with a negative reversal potential EK (Hille, 2001). 
The identification of sodium channel proteins began as radioactive 
tetrodotoxin (TTX) and saxitoxin (STX) became available (Henderson & Wang, 
1972). Using electric eel organs, the size of the protein that can bind to the 
radioactive TTX and STX was revealed to be around 230 kDa (Levinson & Ellory, 
1973). It was predicted that this protein should also contains an additional 30% 
by weight of covalently attached sugar chains and 6% fatty acids (Agnew et al., 
1978; Miller & Robyt, 1983; Levinson et al., 1990). With the evolution of the 
protein chemistry and molecular biology techniques, we now know the complete 
amino acid sequence of the voltage-gated sodium channels. In addition, we now 
know that sodium channels display developmental and tissue specific expression 
(Mandel, 1992; Black & Waxman, 1996; Goldin, 2001; Dominguez et al., 2008; 
Chopra et al., 2010). We also know that the sodium channel α subunit has a 
molecular weight of about 260 kD. The high molecular weight is caused by 
glycosylation (Schmidt & Catterall, 1986, 1987). So far, we know not only the 
amino acid sequences that form the aqueous conduction pore, but also the 
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details about the gating charges that contribute to the voltage sensitivity of the 
sodium channel. 
Sodium channel consists of a pore-forming α subunit and one or more 
modulatory auxiliary β subunits (Figure 2). The α subunit is composed of four 
structurally homologous domains (Sato et al., 1998), namely DI (domain I) to DIV 
(domain IV). Each domain contains six transmembrane segments (S1-S6). The 
extracellular linker region between each segment 5 and 6 joins together forming 
the channel pore referred to as “P loop” or “P segment”, which controls ion 
selectivity and permeation (Figure 2, 3). This loop exhibits a high degree of 
conservation among the various tissue and organ-specific isoforms across 
species, and determines ion selectivity and conductance properties of the 
channel. In each domain, the P loop exerts a unique contribution towards the ion 
selectivity, ion and toxin binding properties and permeation properties of the 
sodium channel. The pore contains the selectivity filter which is referred to as the 
DEKA ring. The DEKA ring is composed by amino acids of aspartic acid (D), 
glutamate (E), lysine (K), alanine (A). It was found that the DEKA ring contains 
one of these amino acids in each P-loop. It was found that the DEKA ring attracts 
positive Na+ ions and repels negatively charged ions (Backx et al., 1992). 
Importantly, the P loops in DIII and DIV play an important role in sodium ion 
selectivity. Using mutagenesis techniques, a lysine residue in the P loop of DIII 
(K1418 in Nav1.5) was demonstrated to be critical for discrimination for Na+ over 
the divalent charged ion Ca2+ (Heinemann et al., 1992; Perez-Garcia et al., 1997). 
In other studies using the same technique, the tetrad WDGL in DIV of the human 
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cardiac sodium channel Nav1.5 (residues 1713 to 1716) were demonstrated to 
affect the selectivity among monovalent cations (Chiamvimonvat et al., 1996). 
Positively charged residues at every third position (with mostly nonpolar residues 
intervening between the basics residues) on S4 segments act as voltage sensors, 
which can lead to the fast activation (opening) of the sodium channel when the 
membrane potential is depolarized. Stuhmer et al. performed site-directed 
mutagenesis to identify the functional regions on S4 of the sodium channel 
(Stuhmer et al., 1989). To test the proposed role of S4 as a voltage sensor, they 
introduced point mutations into the S4 region so that positively charged amino 
acid residues are replaced by either negatively or neutral charged residues. They 
saw a decrease in the steepness of the voltage dependence of activation due to 
the reduction of the net positive charge. Their studies provide experimental 
evidence for the direct involvement of the positive charged residues in this 
segment in the voltage sensing process for activation.  
After the channel is activated, for a period of time varying from 
milliseconds to a few seconds, the channel is unable to open again due to the 
channel gating process called “inactivation”. Inactivation is the process that 
terminates the current (Hodgkin & Huxley, 1952a). There are two types of 
inactivation: one is fast steady-state inactivation, which happens for a period of 
milliseconds. The other type of inactivation is the so-called “slow inactivation”, 
which was comes into play when the channel is depolarized for hundreds of 
milliseconds. The slow inactivation can be sustained for a few seconds.  
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With the development of the molecular biology and advanced biochemistry 
techniques, we now know that certain regions of the sodium channel are 
responsible for channel fast inactivation. These regions are: the IFM motif with 
three hydrophobic amino acids Ile-Phe-Met (West et al., 1992) in the segment 
between transmembrane domain III and IV (DIII, DIV), the intracellular linker 
between S4 and S5 of DIII and DIV, the P loop, and the C-terminal domain of the 
sodium channel (Glaaser et al., 2006).  
Studies for identifying the intracellular cytosolic loop as the structure that 
is responsible for inactivation include: 1) Realization of the inactivation as a 
process that can terminate the transient inward Na+ current (Hodgkin & Huxley, 
1952a). 2) Perfusion of the intracellular surface of the sodium channel with 
proteolytic enzyme prevents inactivation, which implicates the requirement of an 
intracellular structure in the inactivation process (Armstrong, 1981). 3) Antibodies 
targeted at the intracellular linker between homologous domain III and domain IV 
completely blocked the fast inactivation of affected single sodium channel 
(Vassilev et al., 1988; Vassilev et al., 1989). 4) Expression of the sodium channel 
as two single individual polypeptides with a cut between domain III and domain 
IV causes an ~20 fold delay of channel inactivation (Stuhmer et al., 1989). 5) 
Small insertion of the amino acids within the intracellular loop III between domain 
III and IV also slows inactivation (Patton & Goldin, 1991). 6) Post translation 
modification of the serine residue through phosphorylation by protein kinase C 
slows inactivation (West et al., 1991). 7) Deletion of a segment containing 10 
amino acids within the intracellular loop III completely blocks fast inactivation 
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(Patton et al., 1992). The above mentioned studies support the hypothesis that 
loop III between DIII and DIV plays an integral role in the inactivation of the Na+ 
channel.  
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Figure 2. Schematic representation of the linear structure of voltage-gated 
sodium channels (VGSCs).  A. The linear schematic structure of voltage-gated 
sodium channel α subunit. The α subunit of the voltage-gated sodium channel is 
a membrane integrated protein, which consists of four transmembrane domains. 
Each domain contains six transmembrane segments (S1-S6), a pore-forming 
region between S5-S6, and a voltage sensor (S4). The α subunit can assemble 
with one or more auxiliary β subunits namely β1-β4. The inactivation gate is 
located on the intracellular loop between transmembrane domain III and IV. B. 
Indicates four of the subunit fold together to form a functional voltage-gated 
sodium channel. “P” represents channel pore region. Panel A and B are modified 
from the review paper written by Yu and Catterall (Yu & Catterall, 2003).  
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Figure 3. Schematic representation of three-dimensional arrangement of 
sodium channel α subunit. Four homologous domains (I - IV) are fold together 
and each domain contains six hydrophobic transmembrane α helices segments 
(S1-S6). This model was first hypothesized and confirmed by Sato and his 
colleagues (Sato et al., 2001). Within each domain, the S5 and S6 are positioned 
adjacent to the central pore region of the channel. Extracellular linker between 
S5 and S6 in each domain forms the P-loop. S1-S3 forms the outer edge of the 
complex and S4 is positioned in the center of the six segments. Putative IFM 
motif with intracellular linker connecting transmembrane domain III (DIII) and 
domain IV (DIV) forms the inactivation gate.  
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D. Introduction and the characteristics of cardiac sodium channel Nav1.5 α  
subunit: tissue distribution, TTX sensitivity and other properties 
Voltage-gated sodium channel family contains at least nine members, and 
each of them is responsible for action potential initiation and propagation. The 
human cardiac voltage-gated sodium channel is a member of the voltage-
dependent sodium channels. The major cardiac sodium channel in the heart is 
Nav1.5 (Yu & Catterall, 2003). Cardiomyocytes also express the neuronal Nav 
channel isoforms, such as Nav1.1, Nav1.3, and 1.6, but the location of these 
channels are solely on the T-tubules (Maier et al., 2004). The Nav1.5 isoform was 
found at high levels in adult rat heart (Rogart et al., 1989). Although Nav1.5 was 
found in the heart tissue, it is not detectable in adult skeletal muscle. However, 
Nav1.5 isoform is detectable in embryonic, neonatal skeletal muscle and 
denervated skeletal muscle (Kallen et al., 1990). Like other types of voltage-
gated sodium channels, these channels contain a principle α subunit and one or 
more auxiliary β subunits. The α subunit is the pore forming subunit, and it can 
form a functional channel when it is expressed alone in the expression system. 
When expressed, this large α subunit accounts for the defining properties of the 
voltage-gated sodium channels. It contains characteristic toxin-binding sites, pore, 
gates, and a voltage sensor. The α subunit is encoded by the SCN5A gene. Most 
mutations that affect the cardiac sodium channel are located on this gene. The 
functions of the auxiliary β subunits are discussed later.  
The tissue distribution of the cardiac sodium channel was demonstrated 
by both immunohistochemistry and RT-PCR experiments. It was found that these 
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channels are localized not only on the cardiomyocyte surface, but also on the 
surface of T-tubules. Later on, it was also demonstrated that the cardiac sodium 
channel also exists at the terminal of the intercalated disc (Cohen, 1996; Maier et 
al., 2004). As specialized membrane domains, intercalated discs separate 
adjacent cells and contain gap junctions that are responsible for propagating the 
cardiac action potential. The specialized distribution of Nav1.5 as compared to 
the neuronal forms of sodium channel in the heart suggest that it may be crucial 
for action potential initiation while the action potential jumps from one cell to the 
other within the fibers. However, the distribution of the neuronal forms of sodium 
channels within the heart suggests that they are responsible for conducting the 
action potential into the inside of the cell to activate the contractile machinery 
(Cusdin et al., 2008).  
One of the characteristics of the cardiac sodium channel Nav1.5 is lacking 
the sensitivity to a toxin called tetrodotoxin (named by K.S. Cole as “TTX”), a 
paralytic poison from puffer fish such as fugu. The low sensitivity to TTX makes 
the cardiac sodium channel Nav1.5 different from the neuronal and skeletal 
muscle isoforms (Leffler et al., 2005). For those sodium channels that are TTX 
sensitive, their currents can be blocked by nanomolar concentrations of TTX 
(Leffler et al., 2005). The identity of a single amino acid residue in the P loop 
within domain I (DI) determines the differential sensitivities to TTX. It is tyrosine 
401 in Nav1.4, serine 356 in Nav1.8 and serine 355 in Nav1.9 that determines 
the channel’s sensitivity to TTX. TTX sensitive sodium channels carry aromatic 
residues (Phe, or Tyr) at extracellular pore openings. The presence of a 
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hydrophilic cysteine residue at amino acid 374 instead of an aromatic residue 
within the cardiac Nav1.5 channel renders the channel relatively resistant to TTX 
(Satin et al., 1992a; Leffler et al., 2005), such that the current can be blocked 
only by applying micromolar concentrations of TTX.  
The electrophysiological properties of Nav1.5 are generally similar to 
those of the CNS channels, but there are some important differences. The 
membrane potential at which Nav1.5 inactivates is more negative than that of 
other isoforms of sodium channels such as the CNS isoforms (16 mV more 
negative compared to Nav1.2) when the α subunit is expressed alone in Xenopus 
oocytes (Mantegazza et al., 2001). Nav1.5 inactivates more slowly than other 
isoforms such as Nav1.2 (White et al., 1991; Satin et al., 1992b; Mantegazza et 
al., 2001).  
E. Introduction of sodium channel β subunits 
There are four sodium channel β subunits (β1 to β4) that have been 
identified so far. These four subunits can be divided into two groups. One group 
contains β1 (encoded by SCN1B, localized in brain neuronal tissues, skeletal 
muscle and cardiac tissue (Makita et al., 1994)), and β3 (encoded by SCN3B, 
localized primarily in neuronal tissue (Morgan et al., 2000). β3 has been detected 
in the heart (Morgan et al., 2000; Dhar Malhotra et al., 2001; Fahmi et al., 2001). 
β1 and β3 are very similar in amino acid sequence and they are classified as 
noncovalently linked with α subunits (Isom et al., 1992; Morgan et al., 2000). 
Studies indicates that the β1 subunit interacts with DI and DIV of the α subunit 
(Makita et al., 1996). Co-expression of β1 subunit with α subunit modulates 
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channel gating kinetics. It has been shown that co-expression of the β1 subunit 
with the neuronal or skeletal muscle α subunit in Xenopus oocytes increases the 
cell surface channel expression. Further, channel inactivation and activation rates 
were both altered. Channel inactivation curve was shifted to more negative 
potentials when β1 subunit was co-expressed with the cardiac sodium channel α 
subunit (Makita et al., 1994; Nuss et al., 1995). Lori Isom’s group studied the 
expression of α and β subunits in heart tissue, and identified Nav1.1 α subunit, 
Nav1.5 α subunit, β1, and β2. The developmental time course of β2 subunit 
expression suggests that it is at detectable levels from postnatal day 15. Both 
Nav1.5 and Nav1.1 were shown to be co-expressed with β1 and β2 subunits 
(Dhar Malhotra et al., 2001). In cardiomyocytes, it was shown that although the α 
subunit associates with both β1 and β2 subunits, only the β1 subunit has a 
modulatory effect on the electrophysiological properties of Nav1.5. The β2 subunit 
seemingly has no detectable effects on electrophysiological properties of cardiac 
sodium channels, suggesting that the effects of β2 in heart in vivo may involve 
cell adhesion and cytoskeletal communication instead of directly modulating 
channel gating (Dhar Malhotra et al., 2001). Based on the above mentioned 
expression and functional patterns, the α subunit was solely coexpressed with β1 
subunit in my thesis work.  
F. Action potential and its correlation with ECG study 
Ions and currents move across cell membranes in response to electrical 
and concentration gradients through several specific ion channels or transporters. 
In a normal situation, the cardiomyocyte maintains a resting membrane potential 
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of -80 mV to -90 mV, which is relatively negative in comparison to the exterior 
membrane. This gradient is maintained by the pumps such as Na+-K+-ATPase as 
well as fixed anionic charges in the cells (Goodman et al., 2001). Although there 
are both electrical and chemical gradient for sodium ions, the sodium channels 
are voltage-gated and are closed at the negative resting membrane potentials. 
Therefore, Na+ does not enter cardiomyocytes under resting potentials (Figure 4). 
However, specific types of potassium channels such as the inward rectifier 
potassium channels are open under negative resting membrane potentials and 
can allow K+ to move across the cell membrane in response to electrical and 
chemical gradients.  
When the cardiomyocyte is depolarized above a voltage threshold, the 
sodium channel will change its conformation from a closed resting state to an 
open activated conducting state. Thus, about 107 Na+ ions can enter the cell per 
second (Goodman et al., 2001). The activation of a sodium channel can only last 
for a few milliseconds (Ulbricht, 2005). The opening and activation of the sodium 
channel will lead to the depolarization phase of an action potential (called “0” 
phase of the action potential). The inward current generated by the inward 
sodium current can, in turn, cause a series of openings and inactivations of some 
other types of channels, such as transient outward potassium channels (4-AP 
sensitive transient outward K+ current Ito1, and Ca
2+-activated Cl- current Ito2) 
(Kenyon & Gibbons, 1979; Kenyon & Sutko, 1987), L-type and T-type calcium 
channels, delayed rectifier potassium channel (IKs, IKr, and IKur), inward rectifier 
potassium channel IK1 (Deal et al., 1996). The above mentioned channels 
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constitute the repolarization phase of the action potential (phase 1 to 3 of cardiac 
cells). Figure 5 summarizes the relationship of ECG and the human cardiac 
action potential. The P wave of the electrocardiograph represents the 
depolarization that spreads from the sinus atrial node throughout the atria. It has 
a duration of 0.08-0.10 seconds (80-100 ms). The QRS complex represents 
ventricular depolarization. The duration of the QRS complex is usually 60 ms to 
100 ms, a short period indicating that the ventricular depolarization occurs rapidly. 
Following the QRS complex, there is an isoelectric period, which is called “the ST 
segment”. The ST segment indicates the time at which the entire ventricle is 
depolarized and is roughly correlated to the action potential plateau phase. The T 
wave represents the repolarization phase of the ventricular action potential, and 
its duration is usually longer than the depolarization phase. In summary, the QT 
interval represents the time for both ventricular depolarization and repolarization. 
Altogether, the QT interval can be used as a parameter to estimate the duration 
of an average ventricular action potential, and there is a negative correlation 
between these two parameters. Depending on the heart rate, the QT interval can 
vary from 200 ms to 400 ms. In reality, physicians use the “corrected QT interval” 
(QTc) to assess the QT interval (Jackman et al., 1988). The QTc interval is 
calculated by measuring QT interval and dividing it by the square root of the R-R 
interval (an interval between ventricular depolarization) using the “Bazett’s 
formula”, which was named after physiologist Henry Cuthbert Bazett. QTc is used 
to calculate the heart rate-correlated QT interval more accurately (Funck-
Brentano & Jaillon, 1993). QTc is usually less than 440 ms, and the long-QTs 
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patient have a QTc interval of > 440 ms (a standard originated by Peter Schwartz) 
(Schwartz, 1985).   
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Figure 4. Electrical and chemical gradients for sodium and potassium 
channel in the resting state. In the resting state, sodium channels do not open, 
and Na+ does not enter the cell. In contrast, inward rectifier potassium channels 
are open, allowing the K+ ion moves across the membrane until the membrane 
potential reaches the potential that is close to the equilibrium potential for K+ (EK). 
Note: This figure is adapted from “Goodman and Gilman’s the Pharmacological 
basis of therapeutics” (Goodman et al., 2001). 
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Figure 5. Action potential and its relationship with the ECG study. This 
figure is modified from Michowitz and Saenen’s work. (Michowitz et al., 2000; 
Saenen & Vrints, 2008). The top panel depicts a standard ECG trace. The lower 
panel represents a typical ventricular action potential. The QRS wave represents 
the depolarization phase of the ventricle, and the T-wave represents the 
repolarization phase of the ventricle. The QT-interval is the measurement of the 
starting point of the Q wave and the end point of the T-wave. The QT-interval is 
the indicator of the length of the action potential duration (APD). Indicated below 
are the currents participating in each phase of the action potential. Sodium 
current is involved in phase 0, phase 1, and phase 2 of the action potential in the 
ventricular cardiomyocyte.  
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G. Overview of the LQTs 
1. History of the identification of LQTs 
LQTs was first described by Jervell and Lange in 1957. The first case of 
LQTs was identified in a family in which several children had congenital bilateral 
neural deafness and QT prolongation manifested by electrocardiogram (ECG) 
study. The children carrying this disease experienced recurrent syncope and 
sudden death. The disease was referred to as “Jervell and Lange-Nielsen 
syndrome” at the time of discovery (Jervell & Lange-Nielsen, 1957). It was found 
that the particular inherited disease case in this family happened to be in an 
autosomal recessive pattern. Almost a decade later, the LQTs was found in other 
families with similar QT prolongation, and the family history suggested autosomal 
dominant inheritance. The symptom was named as “Romano-Ward syndrome”, 
and the affected members suffered from recurrent syncope and sudden death 
(Ward, 1964; Towbin & Vatta, 2001; Bloise et al., 2002). 
2. Diagnosis of the LQTs 
The diagnosis of LQTs is based on the corrected QT interval (QTc) 
measurement defined on page 20. The QT interval is measured from the start 
point of Q wave to the end point of the T wave. Usually, the ECG result from lead 
II allows a better measurement, since the amplitude of the T wave is large 
enough to allow for an accurate identification of the repolarization T wave for the 
ventricle. Over the years, it was found that LQTs is an inherited cardiac 
arrhythmia that causes abrupt loss of consciousness, seizures and sudden 
death(Jervell & Lange-Nielsen, 1957; Romano et al., 1963; Maron et al., 1976; 
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Towbin & Friedman, 1998; Arnestad et al., 2007). The sudden death is due to the 
ventricular tachycardia, such as ventricular fibrillation and torsade de pointes 
(TdP) (Schwartz et al., 1975; Moss et al., 1991). Although TdP (French for 
“twisting of the points”) is a very rare ventricular arrhythmia, it can degenerate 
into ventricular fibrillation and lead to death without immediate medical 
intervention.  
3. Classification of the LQTs 
There are two types of long-QT syndromes. Besides the inherited LQTs 
that is caused by genetic defects, there is also a type of LQTs so called “drug-
induced LQT syndrome” or “acquired LQT syndrome”.  
a. Genesis of the acquired LQTs 
Compared to inherited LQTs, drug-induced LQTs is far more common, and 
can be acquired as a side-effect of treatment with clinical medications such as 
antiarrhythmic, antihistamine, and psychoactive medications. The “acquired” 
LQTs and TdP were reported in the 1970’s. The administration of certain drugs 
caused reversible LQTs with a high risk of sudden death. The acquired LQTs is 
mostly caused by drugs and/or electrolyte disturbances that alter the 
electrochemical conditions required for normal cardiac excitability. Theoretically, 
drug-induced LQTs can be caused by the reduction of any known voltage-gated 
potassium channel that participates in the cardiac action potential. The molecular 
mechanism for acquired LQTs is almost exclusively found to be the reduction of 
Ikr current through direct or indirect down regulation or blockade of the channel, 
which is encoded by the human ether-a-go-go related gene “HERG” (Yang et al., 
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2002). HERG channels carry the current of Ikr. There are several risk factors that 
can contribute to the acquired LQTs as a complication of drug therapy. These 
factors include gender difference (higher incidence in female), hypokalemia, 
hypomagnesaemia, hypocalcemia, congestive heart failure, congenital structural 
heart defect, left ventricular hypertrophy, bradycardia, atrial fibrillation, high 
plasma drug concentration (Roden, 2006).  
b. The molecular basis of the congenital inherited LQTs 
Since the first identification of genetic mutations that cause LQTs in 1991, 
mutations have been discovered in 12 different genes. The classification of the 
inherited LQTs was based on the chronological order in which the location of the 
mutation was identified. In the population that has been identified to carry LQTs, 
about 50% was associated with mutations. So far, more than 150 mutations have 
been found in the 12 different LQTs associated genes (see Table 1). Mark 
Keating’s group was the very first group to map three LQT loci: LQT1 on 
chromosome 11p15.5 (Keating et al., 1991a; Keating et al., 1991b), LQT2 on 
7q35-36 and LQT3 on 3p21-24 (Jiang et al., 1994). The major strategy they used 
to identify LQT genes is called “candidate gene approach”, which relies on 
hypotheses based on the fundamental physiology knowledge. Since then, more 
LQT subtypes were found and characterized. Inherited LQTs is thought to be 
caused by mutations on certain genes. The majority of the mutations happen to 
be on the genes coding for potassium channels such as KCNQ1, and HERG, and 
they account for about 88% of the mutations that were identified. In fact, the 
LQTs are predominantly ion channel disorders, although genes coding for 
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channel modulatory proteins were also identified a few years later to be the 
cause of other types of LQTs. It was found that sodium channel mutation is 
associated with LQT3, and sodium channel mutations account for about 7% of 
the total identified LQTs-causing mutations. The typical ECG study for LQT3 will 
indicate the long ST-segment interval before the onset of a late prominent T wave, 
and this is the characteristic of LQT3 phenotype. The first SCN5A mutation was 
identified by Mark T. Keating’s group (Wang et al., 1995). They found a three 
amino acid KPQ deletion at position 1505-1507 of the α subunit in affected 
members of two distinct families with LQTs history. This deletion was not 
identified in the control individuals with the sample size of more than 500 healthy 
individuals. This three amino acid in-frame deletion Lys-1505, Pro-1506, Gln-
1507 was predicted to be in the cytoplasmic linker between DIII and DIV. The 
presence of exactly identical deletions in two unrelated families with LQTs history 
strongly suggests that SCN5A mutation is the likely cause of LQT3. KPQ deletion 
is the most extensively characterized SCN5A mutations. In 1995, Bennett et al. 
reported the biophysical properties of this mutant channel. They showed that fast 
inactivation of the mutant channel is delayed since time constants for current 
decay were decreased in the ∆KPQ mutant (WT-hH1: τ fast = 1.47 ± 0.11 ms, τ slow 
= 8.59 ± 0.71 ms; ∆KPQ: τ fast = 0.98 ± 0.07 ms, τ slow = 5.40 ± 0.55 ms, p < 0.01; 
data are means ± s.e.m.) not increased as was predicted. However, unlike WT-
hH1, there are abnormal sustained sodium current (Isus) in ∆KPQ expressing cells. 
The Isus (~ 5% of the peak inward current at -20 mV) was shown not to decay 
within a 200 ms depolarization pulse (Bennett et al., 1995; Wang et al., 1996). 
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Single channel recordings demonstrated that the ∆KPQ channels present 
multiple intermittent reopening after the first 20 ms. This reopening induces an 
Isus or delayed inactivation. In theory, mutations in cardiac sodium channel gene 
could cause LQT. Voltage-gated sodium channels underline the rapid 
depolarization phase in ventricular cardiomyocytes and also conduct a small 
portion of current during the plateau phase of the action potential (Attwell et al., 
1979). Therefore, a subtle abnormality of sodium channel function such as 
delayed sodium channel inactivation, or altered voltage dependence of channel 
inactivation, this could delay the cardiac repolarization phase. As a result, sodium 
channel functional defects can lead to QT interval prolongation and arrhythmia.  
So far, there are transgenic mouse models of ∆KPQ and N1325 mutants. 
In vivo studies from these mice indicate the presence of prolonged QT interval, 
spontaneous ventricular tachycardia and ventricular fibrillation. In vitro 
electrophysiology studies indicated that cardiomyocytes from these mice have 
prolonged APD, increased Isus, and early afterdepolarizations (Fabritz et al., 2003; 
Tian et al., 2004). Typically, the SCN5A mutations that are correlated with LQT3 
are gain-of-function mutations. Studies have demonstrated that gain-of-function 
mutations disturb the delicate balance between outward and inward currents 
which are involved in the plateau phase of the action potential repolarization 
process. In the presence of APD prolongation, there is a propensity for 
cardiomyocytes to develop early afterdepolarizations, which can trigger TdP. 
Under normal conditions, during the plateau phase nearly 99% of the channels 
become inactivated and transitioned into a non-conducting state while the 
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remaining channels stay in the open activated state, sustaining a small window-
current that contributes to the plateau phase. Therefore, mutations that disrupt 
the inactivation process will dramatically enhance the window-current and give 
rise to the prolonged action potential duration (Bennett et al., 1995).  
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H. Sodium channel α subunit mutations and cardiac arrhythmias
1. Role of the cardiac sodium channels in the genesis of the inherited 
cardiac arrhythmias 
In general, as has been discussed before, sodium channels contribute 
predominantly to two phases of the action potential: phase 0, the period of fast 
depolarization of the action potential; and phase 2, the plateau phase of the 
action potential. Mutations in the cardiac sodium channel are associated with 
cardiac arrhythmia. Mutations in the sodium channel contributes to the genesis of 
cardiac arrhythmia through two basic mechanisms: one is loss-of-function 
mutations that lead to the non-functional sodium channels, or channels that can 
inactivate faster; the other mechanism is gain-of-function mutations which 
consequently cause slowing of inactivation and an increase in the late sodium 
current. Increase in the late sodium current leads to the prolongation in cardiac 
action potential duration and the corrected QT interval on ECG.  
2. Inherited LQTs and its relationship with sodium channel gain-of- 
function mutations 
LQTs is an abnormality of cardiac muscle repolarization that predisposes 
affected individuals to a ventricular arrhythmia that can degenerate into 
ventricular fibrillation and cause sudden death. LQTs patients often present with 
a series of symptoms such as QT interval prolongation, polymorphic ventricular 
tachycardia, and sudden death (Jervell & Lange-Nielsen, 1957; Romano et al., 
1963; Ward, 1964). While QT prolongation by itself is not harmful, it can provide 
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the basis for the life-threatening ventricular tachycardia (VT) such as Torsade de 
Points due to its morphological characteristic of changing QRS amplitude.  
3. Sodium channel loss-of-function mutations  
a. Brugada syndrome 
It was first described by Brugada in 1992 (Brugada & Brugada, 1992). 
This is described as a syndrome with recurrent episodes of aborted sudden 
death, right bundle branch block, persistent ST segment elevation, and normal 
QT interval. These patients have structurally normal hearts.  
The first gene that is linked to the Brugada syndrome was reported in 
1998 by Chen and colleagues in Dr. Wang’s and Towbin’s laboratory (Chen et al., 
1998). Using a candidate gene approach, Chen et al. examined six families with 
Brugada syndrome and identified C to T base substitutions in exon 21 and exon 
28 of the cardiac sodium channel gene SCN5A. These mutations lead to the 
substitution of an arginine (R) by a tryptophan (W) at codon 1232, and the 
substitution of a highly conserved amino acid theronine (T) by a methionine (M) 
at 1620. The R1232W missense mutation was found to be located in the S1-S2 
extracellular loop of DIII. The T1620M missense mutation was identified to be 
located in the extracellular loop S3-S4 of DIV. Using Xenopus oocytes, Wang 
demonstrated that sodium channels with the missense mutation recover from 
inactivation more rapidly than normal. In addition, the voltage dependence of 
steady-inactivation was shifted almost 10 mV towards more positive potentials in 
oocytes expressing both R1232W and T1620 mutant channels. Unlike LQTs-
related mutants, these two missense mutants do not cause persistent, 
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inactivation-resistant currents. Electrophysiological studies carried out by Baroudi 
et al. suggested that in mammalian cells such as tsA 201 cells, the T1620 
mutation led to a slower recovery from inactivation with no effect on steady-state 
inactivation (Baroudi et al., 2000). Baroudi’s finding supports the idea that the 
slower recovery from inactivation could decrease sodium current density during 
the cardiac cycle. Therefore, his finding could explain part of the arrhythmia 
phenotypes seen in patients with Brugada syndrome. Other mutations indentified 
by Chen (Chen et al., 1998) were found to produce a stop codon, resulting in the 
elimination of DIII/S6 and DIV/S1-S6. Therefore, the number of functional sodium 
channels will be reduced as a consequence of the stop codon. So far, Brugada 
syndrome related sodium channel mutations are considered to reduce the 
number of functional sodium channels or accelerate their inactivation.  
b. Progressive conduction system defects  
Progressive conduction system defects were first described by Lenegre 
and Lev et al. (Lenegre, 1964; Lev et al., 1970). This disease has a characteristic 
of right or left bundle branch block, which may lead to complete heart block. 
Patients with conduction system defects usually presented with syncope and 
heart block. Later, the gene that causes this defect was mapped to the cardiac 
sodium channel gene SCN5A, which produced a channel lacking S4 of DIII. It 
was shown by histology studies that the heart with conduction system defects 
develops significant fibrosis in the conduction system.  
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I. Antiarrhythmic drug binding sites on sodium channel 
Sodium channel blockers such as lidocaine and quinidine are still widely 
used drugs in terminating cardiac arrhythmia by slowing cardiac conduction and 
prolonging refractoriness period. Hille and Hondeghem proposed models of drug 
actions by binding to a specific site on the channel protein (Hille, 1977; 
Hondeghem & Katzung, 1977). Using alanine scanning mutagenesis method, 
DIV/S6 was examined as a site of action of sodium channel blockers such as 
local anesthetics (Ragsdale et al., 1994). The corresponding regions of the 
cardiac sodium channel were confirmed to have similar function as the drug 
access and binding sites (Ragsdale et al., 1996). Work by Sunami et al. also 
explored the cysteine residue in the linker region between S5 and S6 in domain I, 
and showed that this site may contribute to the cardiac selective binding site for 
sodium channel blocker (Sunami et al., 1997). Further studies need to be 
performed to identify other residues that bind to local anesthetics and 
antiarrhythmic drugs.  
J. Hypothesis and specific aims 
As a rare but lethal inherited cardiovascular disorder, congenital LQTs 
carries a hallmark of prolonged QT interval measured by a surface 
electrocardiograph (ECG). The incidence of congenital LQTs has been estimated 
to be 1 in 5000 to 10000 live births (Nemec et al., 2003; Crotti et al., 2008; 
Schwartz et al., 2009). The episodic ventricular tachycardia such as ventricular 
fibrillation and torsade de points can consequently be triggered by LQTs. So far, 
congenital LQTs has been linked to mutations in 12 different genes including 
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SCN5A, the gene that encodes the cardiac sodium channel Nav1.5 (Hedley et al., 
2009).  
Nav1.5 is the major form of voltage-gated sodium channels (VGSCs) in 
the heart (Rogart et al., 1989), and these channels are essential for the initiation 
and propagation of action potentials throughout different cardiac tissues. These 
channel proteins are composed of a complex of a ~260 kD pore forming α 
subunit and one or more auxiliary β subunits (32-36 kD). Like other types of 
VGSCs, Nav1.5 can undergo conformational changes between closed non-
conducting, open ion-conducting and inactivated non-conducting states in 
response to the changes in the local electric potential across the cell membrane. 
Mutation of SCN5A is considered as the cause of LQT3 (Wang et al., 1995). 
Typically, gain-of-function SCN5A mutations increase late sodium current by 
disruption of sodium channel inactivation, which was predicted to lead to the 
prolongation of action potential duration (Bankston et al., 2007b).  
The α subunit of sodium channel consists of four structurally homologous 
domains (DI-DIV), each containing six transmembrane segments. The 
intracellular loop between domain III and IV is thought to play an important role in 
channel fast inactivation (Figure 6). Within this region, the motif with three 
hydrophobic amino acid IFM (Isoleucine, Phenylalanine, Methionine) was 
demonstrated to be critical for channel inactivation (West et al., 1992). Triple 
mutation of IFM to QQQ (glutamine) and single point mutation of F 
(phenylalanine, Phe) to Q have been shown to slow the inactivation of Nav1.2 
(West et al., 1992). So far, it is still not clear what the specific role that deletion of 
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F1486 plays in regulating biophysical properties of Nav1.5. In addition, it is 
unknown whether deletion of F1486 can modulate the channel’s pharmacological 
response to antiarrhythmic drug such as lidocaine. Previous studies found that 
although the F to Q mutation impairs sodium channel inactivation, it does not 
alter lidocaine sensitivity (Balser et al., 1996). The abnormal channel activity 
generated by the LQT3 ∆KPQ deletion mutation, also in the III-IV linker, is 
preferentially targeted by antiarrhythmics (Wang et al., 1997). However, an infant 
patient with severe cardiac arrhythmia (see ECG study result from (Yamamura et 
al., 2010) was identified to carry a De Novo F1486del within the IFM motif (Figure 
6), and this patient showed reduced sensitivity to lidocaine (Yamamura et al., 
2009). Based on this case report, we formed a hypothesis that “Deletion of 
F1486 on intracellular loop III of human Nav1.5 could alter the biophysical 
properties of the channel, and causes refractory pharmacological response to 
lidocaine”. The aim of this study is to determine the electrophysiological 
consequence of deleting F1486 and investigate the role of Phe in determining the 
response to lidocaine. This is the first report to study the overexpression of LQT3 
mutations in transfected native cardiomyocytes.  
Although disease causing channelopathies are relatively rare, 
investigating the biophysical and functional consequence of these mutations will 
increase our knowledge on the roles that sodium channel plays in controlling the 
excitability of the cardiac cells. Understanding the biophysical response of the 
mutant sodium channels to particular pharmacological drug treatments will help 
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to improve the pharmacological approach to individual patient. Therefore, the 
specific aims of this thesis are:  
1 To determine if deletion of F1486 on hNav1.5 affects the electrophysiological  
properties of the channel using both HEK293 cells and neonatal rat 
cardiomyocytes.  
2 To determine the functional consequence of F1486del on cardiac action  
potential using neonatal rat cardiomyocytes.  
3 To determine if the F1486del mutant channel has reduced response to the  
antiarrhythmic drug lidocaine.  
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Figure 6. Schematic representation and sequence alignment of Homo 
sapiens VGSCs. The top panel is the linear representation of Homo sapiens 
voltage-gated sodium channels (hNav) alpha subunit structure. Amino acids IFM 
which form the putative inactivation motif on the intracellular linker between DIII 
and DIV are shaded in grey. The voltage sensor on segment 4 of each domain is 
marked with “+” and highlighted in grey color. Below is the sequence alignment of 
all types of hNav. There is a 100% sequence identity for the IFM motif. The site of 
phenylalanine (F) deletion in our study is located in the center of IFM motif. 
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II. MATERIALS AND METHODS 
 
A. Ethical information and animal protocols 
Human embryonic kidney (HEK293) cells were ordered from ATCC 
(Manassas, VA, USA). Use of HEK293 cells was approved by the Institutional 
Biosafety Committee and conformed to the ethical guidelines for the National 
Institutes of Health for the use of human derived cell lines. The animal care and 
use protocol was approved by the Animal Resource Center of Indiana University 
and met National Institutes of Health and guidelines for the health and well being 
of the animals.  
B. Animals 
Neonatal Sprague Dawley rats (pups of postnatal day 1: P1) were 
obtained from Harlan-Sprague Dawley, Inc. (Indianapolis, IN, USA). Animals 
were housed in the Laboratory of Animal Source Center (LARC) and used on the 
day of arrival. All procedures used in these studies were approved by the Animal 
Care and Use Committee at Indiana University School of Medicine, Indianapolis, 
IN.  
C. Patch-clamp recording related instrument set up and general 
experimental procedures 
The patch-clamp set up rig contains an inverted microscope stage (Nikon 
Instruments Inc., Melville, NY, USA), which was equipped with a white (Nikon 
TE2-PS 100W) and fluorescent halogen light source (X-cite 120, Photonic 
Solutions Inc, Mississauga, ON, Canada), dual Nikon ocular lenses, and Nikon 
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contrast objectives (10 ×, and 40 ×). The rig also contains an isolated nitrogen 
infused air table (50-60 psi maintained air pressure) with a 2 inches stainless 
steel laminate (63-500 Series, Technical Manufacturing Company, Peabody, MA, 
USA). The function of the air table is to prevent vibration of the microscope and 
the recording chamber. The air table was grounded with metal wire to be 
connected to the ground input of the amplifier.  
Detailed description of the patch-clamp technique can be found online 
from Axon or HEKA websites. In general, cells were selected based on their 
morphology and expression of EGFP. A polished glass electrode pipette was 
back filled with the appropriate intracellular solution. After filling with intracellular 
pipette solution, the ideal pipette resistances for recordings are around 0.9-1.3 
MΩ in HEK293 cells, and 1.5-2.5 MΩ in neonatal cardiomyocytes. Liquid junction 
was adjusted to zero before forming the seal. Whole cell patch-clamp recordings 
were started after obtaining a Giga Ohm seal, which is formed between the glass 
pipette tip and the cell lipid membrane layer. The typical seal that can be 
achieved is around 1-20 GΩ.  
D. Preparation of the patch-clamp recording chamber  
The patch-clamp recording chamber was home-made and designed 
based on a 35 mm cell culture dish (Corning, Inc, Corning, NY, USA). The 
chamber was filled with silicone elastomer base (Sylgard, World Precision 
Instruments Inc.®, Sarasota, FL, USA), which was mixed with curing agent, and 
allowed to solidify. After the solidification, a 12 mm glass coverslip was placed in 
the center of the silicone coated dish and a razor blade scalpel was used in order 
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to cut the edge surrounding the glass coverslip. The loose inner portion was 
discarded after the edge surrounding the coverslip was completely removed from 
the chamber. The center portion of the chamber will be large enough to hold up 
to approximately 300 μl recording solution. 
E. Mutagenesis of VGSCs 
hNav1.5 cDNA (wild type or mutant hNav1.5 cDNA) was subcloned into 
pcDNA3.1 (+) vector (Invitrogen, Carlsbad, CA, USA) using HindIII (5’ end) and 
XbaI (3’ end) as restriction enzyme sites. Site-directed mutagenesis of voltage-
gated sodium channels was performed to characterize voltage-dependent effects 
of single-point mutation on several constructs (Nav1.5 WT, F1486del, G1481E). 
An additional mutation is required to engineer a second chimeric point mutation 
in both wild type and disease causing SCN5A sequences to endow the channels 
with enhanced resistance to TTX (~100 μM). Biophysical and biochemical 
properties of channels were examined using voltage-clamp, current-clamp and 
western blot experiments. Mutagenesis primers were designed to introduce the 
correct base pair change into wild type hNav1.5 channel cDNA using Vector NTI 
software (Invitrogen, Carlsbad, CA, USA). WT hNav1.5 with appropriate 
nucleotide changes resulting in hNav1.5 F1486del was produced using Quick 
Change XL site-directed mutagenesis kit (Agilent technologies, Santa Clara, CA, 
USA) according to the manufacturer’s protocol. Full-length sequence was 
analyzed using ACGT (Wheeling, IL, USA) plasmid DNA sequencing services to 
verify the specific mutation at the targeted site. Primers that were used to 
generate human Nav1.5 cDNA mutation constructs are listed in Table 2. 
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The sequencing primer for hNav1.5 WT and F1486del construct is:  
5’-AACCTCTACATGTACATCTAT-3’ 
The primer for sequencing the hNav1.5 G1481E mutation product is: 
5'- AAC AAC AAG AGC CAG TGT GAG TCC -3' 
Primers used in full-length sequencing analysis are listed in Table 3. 
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Table 2. Primers used for generating hNav1.5 mutant cDNA constructs 
Primer Name Sequence (5’ to 3’) 
F1486del Forward GGCCAGGACATCATGACAGAGGAGC 
F1486del Reverse GCTCCTCTGTCATGATGTCCTGGCC 
G1481E Forward CAGAAGAAAAAGTTAGAGGGCCAGGACATCTTC 
G1481E Reverse GAAGATGTCCTGGCCCTCTAACTTTTTCTTCTG 
TTXR Forward CTGATGACGCAGGACAGTTGGGAGCGCCTCTATC 
TTXR Reverse GATAGAGGCGCTCCCAACTGTCCTGCGTCATCAG 
 
 
  
44 
 
Table 3. Primers used in full-length sequence analysis of sodium channel 
Nucleotide Position Sequence (5’ to 3’) 
364-386 ACC TGC AGG CCT CCA AAA AGC TG 
816-839 GAA TTT GTG GAC CTG GGC AAT GTC 
1566-1586 CGT AGC TCC TTG GAG ATG TCC 
2726-2750 GGT GCT AGC CAT CAT CGT GTT CAT C 
3432-3452 CCT GTG TCC GGT GGC CCA GAG 
4084-4104 CCA TCA AGT CAC TGC GGA CGC 
4807-4830 GCT TGA ATA TGG TGA CCA TGA TGG 
5497-5519 GCT TGA ATA TGG TGA CCA TGA TGG 
6139-6159 CCA CCA GCG ATA ACC TCC AGG 
6792-6814 GCT GAA CCC CCA CTC ACA CAA GC 
7467-7487 CCA TGG CAC CTT TGA GAG AGG 
8116-7488 GCT TGG AGA GGT ATG TGC CC 
All sequencing primers were designed to test the correct base-pair change 
in the hNav1.5 construct, and to confirm there is no nonspecific mutation.  
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F. Large-scale bacteria culture and DNA purification 
Bacterial colonies were grown up according to the Strategene’s 
QuickChange® protocol. After antibiotic-resistant colonies had grown on 
LB/antibiotic agar plates, several single individual colonies were picked using 20-
200 μl pipette tips. Each individual colony was then transferred to a 14 ml sterile 
round bottom Falcon tube (Becton Dickinson Labware, Franklin Lakes, NJ, USA) 
containing 5 ml of LB broth and penicillin (100 μg/ml) to initiate the mini culture. 
The mini bacteria cultures were then placed in a 37 oC Excella E25 incubator 
(NewBrunswick Scientific, Edison, NJ, USA) at a shaking speed of 250 rpm and 
incubated overnight. Bacteria mini culture plasmid purification was performed 
using Promega Pure Yield Plasmid Miniprep Kit (Promega, Madison, WI, USA). 
All procedures were performed according to the manufacture’s protocol. Once 
the plasmid DNA was purified, the constructs were screened and confirmed by 
restriction enzymatic digestion, and DNA sequencing based on the appropriate 
DNA sequencing primers. Full-length DNA sequencing was performed using the 
DNA sequencing service from ACGT Company (ACGT, Wheeling, IL, USA). After 
the sequence of the construct was verified, large scale bacteria cultures 
(MaxiPrep) were performed in order to obtain sufficient amount plasmid DNA for 
the downstream studies. The purification of plasmid DNA from larger scale 
bacterial cultures were performed using Sigma GeneElute HP Plasmid Maxi Prep 
Kit (NA0300, Sigma, St. Louis, MO, USA). After the plasmid purification was 
completed, the yield plasmid cDNA constructs were checked for purity and 
concentration using Nanodrop ND-1000 spectrophotometer instrument (Thermo 
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Fisher Scientific Inc., Wilmington, DE, USA). The concentration was brought to 
0.5 μg/μl using double distilled sterile water. Purified plasmid cDNA constructs 
were then used for transfection in the appropriate expression system.  
G. Cell culture 
1. Culture of HEK293 cells  
HEK293 cells (from ATCC, American Type Culture Collection, Manassas, 
VA, USA) were grown on 35mm tissue culture dishes (Corning Inc, NY, USA) 
under standard tissue culture conditions (37 oC; 5% CO2) in Dulbecco’s modified 
Eagle’s medium containing high glucose (DMEM/H, Invitrogen, Grand Island, NY, 
USA) supplemented with 10% fetal bovine serum (FBS, Atlanta Biologicals, 
Lawrenceville, GA, USA), 1% penicillin/streptomycin (Invitrogen, Grand Island, 
NY, USA) and 1mM L-glutamine (Invitrogen, Grand Island, NY, USA). Cell culture 
media was changed every 2-3 days. Cells were replated into new sterile tissue 
culture dishes once the confluency reaches 80% to 90%.  
2. Harvest, isolation and culture of neonatal rat cardiomyocytes 
Neonatal Wistar rats were used in each single preparation. Pups of post 
natal day 1 (P1 pups) were generally used. P1 rats were sacrificed and hearts 
were collected from all pups. Hearts were stored in calcium and magnesium-free 
PBS on ice. Hearts were gently squeezed with forceps to expel the blood from 
the lumen, and then transferred into fresh ice-cold PBS buffer. The atria tissues 
were cut out and the ventricles were saved for the subsequent dissociation 
procedure. The ventricle tissues were then transferred to a new 60 mm sterile 
Petri dish and minced into small pieces with a sterile scalpel blade. The minced 
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neonatal heart tissues were then transferred into a sterile T-25 cell culture flask 
under a laminar flow tissue culture hood. The bottom of the flask was filled with 5-
7 ml of the pre-warmed digestion buffer containing 0.5 mg/ml collagenase and 
0.4 mg/ml pancreatin. The flask containing the cardiac tissues was incubated in a 
37 oC water bath for 30 minutes and the tissues were mixed by gentle shaking. 
The supernatant containing the suspended cells from the first round of the 
digestion were discarded. The remained tissue was saved and the bottom of the 
flask was filled with another 5 to 7 ml digestion buffer. Following these steps, the 
tissues were incubated in the 37 oC water bath for 20 minutes. This step was 
repeated for 5 to 6 times. After each 20-minute digestion, the suspension 
containing the isolated cells was collected and transferred into a 15 ml sterile 
conical tube. 1 ml of horse serum was added to the tube to terminate the 
enzymatic reaction. The tube was centrifuged at 700 rpm for 10 minutes. The 
supernatant containing the enzyme was discarded, and 2 ml of the neonatal calf 
serum was added to the tube. The cells were gently mixed into a suspension by 
tapping the bottom of the tube. 10 ml of complete cell culture medium was added 
to the tube to completely suspend the isolated cardiomyocytes, which were then 
plated into a 10 cm cell culture dish. Eventually, the total isolated cardiomyocytes 
were plated into four to five 10 cm cell culture dishes. The cardiomyocytes were 
incubated under tissue culture conditions (37 oC, 5% CO2) for 1 to 1.5 hours to let 
the fibroblast cells attach. The culture media containing the isolated 
cardiomyocytes was then collected after the centrifugation. Complete tissue 
culture media was added to the tube to resuspend the cells. Cell number was 
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counted using the hemocytometer (Hansser Scientific, Horsham, PA, USA). The 
cardiomyocytes were cultured using DMEM/F12 media containing 10% fetal 
bovine serum, 100 units/ml penicillin, 100 mg/ml streptomycin and 1mM L-
glutamine. Following a 24 hour incubation period, the serum-containing medium 
was replaced with a low serum medium containing medium (0.5% horse serum, 
0.5% fetal bovine serum) called “maintenance medium” to prevent hypertrophy. 
Cardiomyocytes were cultured for up to 48 hours in the maintenance medium. 
Electrophysiology studies were performed within 48 hours post transfection.  
H. Gene transfection  
1. Plasmid map of cDNA construct for human Nav1.5  
DNA encoding human cardiac voltage-gated sodium channel Nav1.5 was 
subcloned into pCDNA3.1 vector. The restriction enzyme cutting site are BamH I 
(5’ end) and Xba I (3’ end). The detailed information is indicated in the vector 
map (Figure 7).  
2. Plasmid map of cDNA construct for N2-EGFP  
cDNA encoding N2-EGFP was used in the transfection, and its product 
green fluorescence protein is used as an transfection control in order to visualize 
the transfected cells. The detailed information about the cDNA construct is 
described in Figure 8.   
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Figure 7. Plasmid map of pcDNA3.1 (+) carrying the gene of Homo Sapiens 
full-length SCN5A encoding hNav1.5. This map was modified based on the 
pcDNA3.1 (+) vector map. The gene was inserted into the vector between BamH 
I restriction enzyme site and Xba I site. The F1486del SCN5A gene carries an 
amino acid deletion at codon 1486. This amino acid is on the intracellular loop 
between transmembrane domain III (DIII) and domain IV (DIV). The total length 
of this plasmid DNA is around 12.8 kb.  
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Figure 8. Plasmid map of cDNA construct for N2-EGFP. The copyright of this 
map belongs to the Clonetech Inc. pEGFP-N2 encodes a mutant fluorescent 
protein (GFP) with enhanced fluorescence as compared to the gene encoding 
WT green fluorescence protein. The total length of this vector is about 4.7 kb. 
EGFP was used as a transfection control in order to visualize the transfected 
cells in the electrophysiology studies.  
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3. Transient transfection of HEK293 cells  
Unless otherwise stated, HEK293 cells were used to express various 
cardiac voltage-gated sodium channel Nav1.5 (WT, or different mutants). Equal 
amount of cDNA encoding sodium channel hNav1.5 α subunit and auxiliary β1 
subunit were transiently cotransfected into HEK293 cells using calcium 
phosphate precipitation method. We chose to express the sodium channel α 
subunit together with the β1 subunit since these two subunits have been shown to 
co-express in cardiomyocytes (Dhar Malhotra et al., 2001). In addition, the β1 
subunit was demonstrated to be able to modulate cardiac sodium channel 
function, while β2-subunit function in heart maybe be limited to cell adhesion 
(Dhar Malhotra et al., 2001). Plasmid DNA encoding N2-EGFP was also used as 
a transfection control in order to visualize the transfected cells which will be used 
in patch-clamp experiments.  
30 minutes before the forming of the mixture of calcium phosphate, 
complete cell culture media was replaced by cell culture media containing 5% 
FBS. Next, the transfection reagents were brought to the room temperature or 
warmed in the 37 oC water bath. The transfection reagents contained: 2 × 
HEPES buffer (1.6 g NaCl, 0.021 g Na2HPO4, 1.3 g Na-HEPES per 100 ml, pH 
was adjusted to 7.0); sterile double distilled water; 2 M CaCl2. Various set of 
sterile 1.5 ml centrifuge tubes were labeled. For each transfection condition, 2 
tubes will be used. The contents of the tubes were as follows, for example: Tube 
# 1, 50 μl 2 × HEPES; tube # 2, 3 μg α subunit per transfection, 0.75 μg β1 
subunit per transfection, 0.75 μg N2-EGFP per transfection, 5 μl CaCl2, and use 
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sterile double distilled water to bring the total volume to 50 μl. The 5 μl CaCl2 was 
added to tube # 2 dropwise last, and mixed evenly. Each tube containing the 
content was allowed to sit in the cell culture hood for 2 minutes before 
combination. Then, the content in tube # 2 containing cDNA was added dropwise 
to tube # 1, which contained the 2 × HEPES buffer. The total content was mixed 
well by tapping the wall of the tube. Then bubbles were formed using the 100 μl 
pipette tip, and this bubble-generating procedure was slowly repeated 5 to 10 
times to allow the fine precipitate grains to be formed. The calcium-phosphate-
DNA mixture was left in the sterile laminar tissue culture hood for 30 minutes to 
allow enough fine precipitate grains to be formed. 30 minutes later, the mixture of 
calcium phosphate and DNA was added to the cell culture medium with 5% 
reduced FBS and maintained in the media for 4-6 hours. After this, cells were 
washed with warmed fresh culture medium containing 10% FBS twice and 
replated onto 12 mm glass coverslips in 24 well plates (Costar, Corning Inc, 
Corning, NY, USA) with each well containing 500 μl to 1ml 10% serum-complete 
medium. Typically, transfected cells were used for whole patch-clamp recording 
within 48-72 hours post transfection, given that this time-window is the best time 
for obtaining optimal expression level and single cell without contacting with 
adjacent cells. Cells were selected based on the expression of enhanced green 
fluorescence protein and used for data collection if current amplitude was greater 
than 500 pA under whole cell recording mode in order to minimize signal to noise 
ratio during data analysis. 
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4. Transfection of neonatal rat cardiomyocytes  
2 × 106 cells were used for each transfection reaction. Briefly, 2 × 106 cells 
in suspension were transferred into a 1.5 ml sterile centrifuge tube and 
centrifuged at 600 rpm for 3 minutes. The supernatant was discarded. Then 100 
μl Amaxa Nucleofector transfection reagent was added to each tube. Then 100 μl 
of cell suspension was combined with 3 μg cDNA encoding α subunit, 2 μg 
pMaxGFP cDNA. Since the neonatal cardiomyocytes contains endogenous β1 
subunit, the cDNA encoding β1 subunit was not included in each transfection. 
The mixture was evenly mixed with the plastic pasteur pipette with fine tips for 2 
to 3 times. The mixture was then transferred into a cuvette for electroporation. 
The cuvette with cell/DNA suspension was transferred into the cuvette holder and 
the program G-009 for cardiomyocyte transfection was applied. The cell 
suspension was transferred into a 15 ml sterile conical tube and 12 ml of 
complete cell culture medium was added to the tube. The cells were mixed with 
the culture media gently and then plated into the 24-well plate containing the 12 
mm coverslip in each well. Patch-clamp recordings were performed 24-48 hours 
post transfection.  
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I. Chemicals  
Detailed information about the chemicals used in the study is listed in Table 4. 
Table 4. Chemical reagents and drugs used in the study 
Chemical Name Manufacture Catalogue Number 
lidocaine Sigma L5647 
TTX Alomone Lab T-500 
NaOH powder Sigma S8045 
NaCl Sigma S7653 
MgCl2 Sigma M8266 
KCl Sigma P9333 
CaCl2 Sigma C1016 
HEPES Sigma H3375 
CsF Sigma 20989 
EGTA Sigma E0396 
sucrose Sigma S7903 
glucose Sigma G7528 
CoCl2 Sigma 60818 
CsOH solution Sigma 232068 
NaH2PO4 Sigma S8282 
Na2-ATP Sigma A26209 
KOH Sigma P5958 
K-Aspartate Sigma A6558 
NaOH solution Sigma S2770 
CsOH solution Sigma 232041 
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J. Solutions 
1. Preparation of lidocaine hydrochloride stock solution 
Lidocaine hydrochloride monohydrate (Sigma Aldrich) was dissolved in the 
standard external recording solution to make a stock solution of 100 mM. The 
stock solution was prepared shortly before the experiment and pH was adjusted 
to 7.3 using 1N NaOH. Subsequent dilutions to concentrations of 10 mM, 3 mM, 
1 mM, 300 µM, 100 µM, 30 µM, 10 µM were performed using the standard 
external bathing solution.  
2. Preparation of tetrodotoxin stock solution  
Citrate-free tetrodotoxin (TTX) powder (Alomone Lab, Israel; catalogue 
number: T-500) was dissolved in 50 mM acetic acid solution, and was further 
diluted to the desired concentration using the external bathing solution for INa 
recording in cardiomyocytes.  
3. Standard extracellular bathing solution for voltage clamp recordings  
from HEK293 cells 
The standard extracellular bathing solutions were used to bathe HEK293 
cells during all whole-cell voltage-clamp electrophysiology studies using 
transfected HEK293 cells. The osmolarity of the solution was adjusted to about 
290 mOsm. The chemical components consisted of (in mM): 140 NaCl, 1 MgCl2, 
3 KCl, 1 CaCl2, and 10 HEPES. pH was adjusted to 7.3 with NaOH.  
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4. Standard intracellular pipette solution for voltage clamp recordings  
from HEK293 cells  
The standard pipette solution for INa recording from HEK293 cells 
contained (in mM): 140 CsF, 10 NaCl, 1.1 EGTA, and 10 HEPES, pH 7.3 
(adjusted with CsOH). Osmolarity was adjusted to around 300 Osm. After 
obtaining the appropriate osmolarity and pH, the internal solution was filtered 
using fast flow and low binding syringe driven 0.22 μM filter unit (Millipore, 
Carrigtwohill, Co, Cork, Ireland) to get rid of any potential substance that can 
block the pipette tip. The pipette solution was then aliquoted into 1.5 ml sterile 
centrifuge tubes and stored in a -20 oC freezer for future use.  
5. Standard extracellular bathing solution for INa recordings from  
neonatal rat cardiomyocytes  
The bath solution for INa recordings was the same as described by Maier 
et al. in 2002. (Maier et al., 2002). The chemical components of the extracellular 
bathing solution consisted of (in mM): 120 NaCl, 1.2 MgCl2, 1.5 CaCl2, 10 
HEPES, 10 tetraethylammoniumchloride, 5.0 sucrose, 5.0 glucose, and 5.0 
CoCl2, pH was adjusted to 7.4 with 1N NaOH.  
6. Standard intracellular pipette solution for INa recordings  
from neonatal rat cardiomyocytes  
The pipette solution contained (in mM): 120 Cs-aspartate, 5.0 NaCl, 2.0 
MgCl2, 10 HEPES, 10 EGTA. pH was adjusted to 7.3 with CsOH. After obtaining 
the appropriate osmolarity and pH, the internal solution was filtered using fast 
flow and low binding syringe driven 0.22 μM filter unit (Millipore, Carrigtwohill, Co, 
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Cork, Ireland) in order to get rid of any potential substance that can block the 
pipette tip. The internal solution was then aliquot into a series of 1.5 ml sterile 
centrifuge tubes, and stored at -20 oC for future use. 
7. Standard extracellular solution for action potential recordings 
from neonatal rat cardiomyocytes  
In order to record the action potential from primary rat neonatal 
cardiomyocytes, tyrode solution was used extracellularly. The tyrode solution 
used for action potential studies contained (in mM): NaCl 126, KCl 5.4, HEPES 
10, NaH2PO4 0.33, MgCl2 1.0, CaCl2 1.8, glucose 10. pH was adjusted to 7.4 
with NaOH. The osmolarity was adjusted to 300 Osm.  
8. Standard intracellular pipette solution for action potential recordings  
from neonatal rat cardiomyocytes  
The current-clamp mode was used in order to study the action potential 
profile from native neonatal rat cardiomyocytes. The pipette solution used in 
current-clamp experiments contained (mM): KCl 20, potassium aspartate 110, 
MgCl2 1.0, HEPES 5.0, EGTA 10, Na2-ATP 5.0. pH was adjusted to 7.2 with KOH, 
and osmolarity was adjusted to around 290 using nanopure water. After obtaining 
the appropriate osmolarity and pH, the internal solution was filtered using fast 
flow and low binding syringe driven 0.22 μM filter unit (Millipore, Carrigtwohill, Co, 
Cork, Ireland) in order to get rid of any potential substance that can block the 
pipette tip. The internal solution was then aliquoted into a series of 1.5 ml sterile 
centrifuge tubes, and stored at -20 oC for future use. 
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K. Whole cell patch-clamp recordings on HEK293 cells  
Whole cell patch-clamp recordings were conducted at room temperature 
(~ 21 oC) using a HEKA EPC-10 amplifier. Data was collected using a computer 
with the Pulse program (v 8.65, HEKA Electronic, Germany). Fire-polished glass 
electrodes were fabricated from capillary glass (VWR International, Radnor, PA, 
USA), which were pulled using a Sutter P-97 puller (Novato, CA, USA) to have a 
resistance of 0.9-1.4 MΩ. Cells on glass coverslips were transferred to the 
recording chamber containing 300 µl of external bathing solution. Series 
resistance was compensated to reduce the voltage error to less than 3 mV. 
Recordings were started 5 mins after forming whole cell configuration to allow for 
sufficient equilibration of the intracellular solution and pipette solution. Lidocaine 
solution was added to the recording chamber by first withdrawing 30 µl of bath 
solution, and then adding 30 µl of 10-fold concentrated lidocaine and mixing 10 to 
15 times using a 100 µl pipettor. Cells were kept in the external bathing solution 
for no more than one hour to allow the healthy condition during patch-clamp 
recordings.  
L. Whole cell patch-clamp recordings from neonatal rat cardiomyocytes 
Whole-cell cardiac sodium current and action potentials were recorded at 
room temperature from rod-shaped cells within 24-48 h post transfection. The 
current-clamp technique was used to record the action potentials from neonatal 
cardiomyocytes. Action potentials were elicited by 2-ms stimulus pulses at 
frequency of 1 kHz. AP measurements were started 5 min after obtaining the 
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whole cell configuration, and the steady-state action potential duration was 
measured at 50% (APD50) and 90% (APD90) of full repolarization. Data sampling 
rate varied from 2 to 2.5 kHz. Cells generating spontaneous oscillatory potentials 
at depolarized potentials were defined to have early afterdeoplarization (EAD). 
TTX was added to the external solution at a final concentration of 20 μM to 
eliminate the contamination of endogenous sodium currents in neonatal 
cardiomyocytes in voltage-clamp studies (Figure 9). No TTX was applied to the 
extracellular recording solution for action potential studies under the current-
clamp mode. Pipette resistance was 1.5-2.5 MΩ when filled with the internal 
solution.  
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Figure 9. Illustration of cDNA sequences coding for recombinant sodium 
channels that are highly resistant to tetrodotoxin (TTX). A. Sequence 
alignment for different VGSCs indicates critical sites that determine the sensitivity 
to TTX. It is the cysteine residue on Nav1.5 that makes the channel relatively 
resistant to TTX (IC50 ~2 μM) as compared to the TTX sensitive channel (White 
et al., 1991; Goldin, 2001). It is the serine residue on Nav1.8 and Nav1.9 that 
endows the channel with even higher resistance to TTX (with an IC50 of either 
~60 μM or above 100 μM) (Akopian et al., 1996; Sangameswaran et al., 1996; 
Goldin, 2001; Leffler et al., 2005). B. Illustration of a part of the recombinant 
sodium channel sequences that were used in my patch-clamp studies in neonatal 
cardiomyocytes. The other parts of the sequences are exactly the same for both 
channel types. Both WT and the F1486del cDNA contain the cysteine to serine 
mutation.  
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M. Cysteine, lysine and arginine specific cell surface biotinylation assay 
Cell surface expression of WT and F1486del mutant proteins was 
analyzed by biotinylation using a cell impermeable reagent (Khanna et al., 2001). 
Briefly, 6 μg of plasmid DNA was transfected into HEK293 cells cultured in a 6 
cm cell culture dish. Four dishes were used for each group. 36-48 h post 
transfection, HEK293 cells were washed twice with cold PBS and then incubated 
at 4 oC for 30 min with EZ-link Sulfo-NHS-LC-Biotin (1 mg/ml; Thermoscientific, 
Rockford, IL, USA) in PBS solution. The cells were then washed with glycine to 
quench the biotinylation reaction. Following this step, cells were washed with 
cold PBS two to three times to remove the excessive biotinylation reagent. The 
cells were lysed using 600 μl ice-cold RIPA cell lysis buffer containing protease 
inhibitors. The lysed cells were incubated on ice for 30 min, vortexed every 5 min, 
and then centrifuged at 4 oC to remove the insoluble component. 5% of the total 
volume of the solubilized protein was reserved for future use. 5 μl of the protein 
from each tube was used for protein concentration measurement using BCA 
assay. The rest of the solubilized material was incubated with 75 μl streptavidin-
linked agarose beads (Thermoscientific, Rockford, IL, USA) at 4 oC overnight. 
The beads were collected by brief centrifugation and washed 3 times with RIPA 
lysis buffer. Precipitated protein was then eluted by boiling in 50 μl gel loading 
buffer at 100 oC for 5 min followed by brief centrifugation. The streptavidin 
precipitated protein and the aliquoted total solubilized protein were subjected to 
electrophoresis using 4-12% acrylamide gels. The proteins were then transferred 
to a PVDF membrane, immunoblotted with a rabbit polyclonal anti-Nav1.5 
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antibody (ASC-005, Alomone Lab, Isareal) and mouse monoclonal anti-β III 
tubulin antibody (G712A). The proteins were then visualized using an enhanced 
chemiluminescent western blotting substrate (Thermoscientific, Rockford, IL, 
USA, prod # 32106).  
N. Preparation of cell lysate 
HEK293 cells were transiently transfected with cDNA coding for WT 
Nav1.5 or F186del channels. Typically, 6 cm sterile cell culture dishes were used 
in these experiments. Before transfection, cells that grow in 6 cm cultures dishes 
reach 80%-90% confluency. 24 hours post transfection, cell culture media was 
aspirated from the culture dishes. Then, the cells were washed with 1×PBS twice. 
500 μl cell lysis buffer was added to each dish. The cell lysis buffer contained: 20 
mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM Na2EDTA, 1 mM EGTA, 1% Triton, 
2.5 mM sodium pyrophosphate, 1 mM beta-glycerophosphate, 1 mM Na3VO4, 1 
µg/ml leupeptin. Cells were then scraped off the plate and transferred to a 1.5 ml 
mircocentrifuge tube. The sample was incubated on ice for 30 minutes, vortexed 
or mixed with the pipette every 5 minutes. The sample was sonicated for 30 
seconds on ice in order to shear the genomic DNA and reduce the viscosity that 
could trap the protein. Thus, the purpose is to increase the protein content that is 
dissolved in the sample. The sample was then centrifuged at full speed for 20 
minutes at 4 centigrade. The supernatant was then transferred to a 1.5 ml 
centrifuge tube and stored in a -80 oC freezer for future use. 
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O. Protein concentration measurement  
Protein concentration was measured using bicinchoninic acid (BCA) assay 
method. BCA assay is a detergent-compatible formulation for the colorimetric 
detection and quantification of protein concentration. In this assay, the Cu2+ was 
reduced to Cu+ under an alkaline medium. One cuprous ion Cu+ was chelated 
with two molecules of BCA, and the purple-colored product was formed. The 
colored product can be detected since it has a strong absorbance at 562 nm. 
BSA was used as a protein concentration standard. The standard BSA is diluted 
to a series of final concentrations (μg/ml): 2000, 1500, 1000, 750, 500, 250, 125, 
and 25. The working BCR reagent (WR) was prepared by mixing 50 parts of BCA 
reagent with 1 part of BCA reagent B (50:1, reagent A:B). Samples were diluted 
with a ratio of 1:10 using 1× cell lysis buffer. 25 μl of each standard or unknown 
sample replicate was added into a single microplate well. Then, 200 μl of the 
working reagent was added to each well and mixed thoroughly. The plate was 
then covered with aluminum foil (Fisher Scientific, Cat No: 01-213-100) and 
incubated in the 37 oC incubator for 30 minutes. Protein concentrations were 
measured using a plate reader at 562 nm wavelength.  
P. SDS-polyarylamide gel electrophoresis of protein and transfer 
50 μg of protein was mixed with 5× sample loading buffer (250 mM Tris pH 
6.8, 10% SDS, 50% glycerol, 0.02% bromophenol blue, add 10% β-
mercaptoethanol as fresh before use) and then heated to 95-100 centigrade for 5 
minutes to denature the protein. The total volume was balanced to the same 
volume for each sample. 50 μg of each protein sample was loaded onto a 5% 
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SDS-PAGE gel. Electrophoresis was performed under a voltage of 80 V for the 
stacking gel and 120 V for the separating gel. After the appropriate separation of 
the protein molecular weight marker, proteins on the gel were transferred onto a 
0.22 μm PVDF membrane (Bio-Rad, Hercules, CA, USA) using a Bio-Rad 
electrotransfer apparatus. The transfer was performed at room temperature for 1 
hour under a voltage of 15 V. The transfer buffer contained 25 mM Tris-HCl (pH 
8.0), 190 mM glycine and 20% methanol.  
Q. Western immunoblotting analysis  
Immunoblotting analysis was used to analyze total Nav1.5 protein 
expression level in HEK293 cells transiently transfected with cDNA coding for WT 
Nav1.5 or F186del channels. 
The membrane containing the transferred proteins was washed with 
1×TBST (10 mM Tris-HCl, 50 mM NaCl, and pH was adjusted to 7.6 with 6N HCl, 
and then add 0.1% Tween-20) for 5 minutes after the membrane was taken out 
from the transfer apparatus. The membrane was then incubated in blocking 
buffer containing 5% non-fat milk at room temperature with constant shaking for 
1 hour. Membrane was then incubated with primary rabbit antibody for Nav1.5 
(Alomone Lab, Israel) for 1.5 hours at room temperature. After the incubation with 
primary antibody, the membrane was then washed 3 times with 1×TBST (10 
minutes for each wash). The membrane was then incubated with secondary 
antibody against rabbit IgG under room temperature for 1 hour. After 3 washes, 
the membrane was exposed to ECL plus (PIERCE, Rockford, IL, USA) liquid 
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mixture for about 1 minute. Autographic film was used to detect the proteins 
following an optimal exposure time period.  
R. Data analysis  
Voltage-clamp experiment data were analyzed offline using the Pulsefit (v 
8.65, HEKA electronic), Microsoft Excel and Prism (GraphPad Software Inc, La 
Jolla, CA) software programs. Normalized conductance-voltage relationships (G-
V) were derived using the function: GNa=IMax/(Vm-ENa) (1). GNa is conductance of 
sodium channel, IMax is the peak current density in response to the test pulse, Vm 
stands for the test pulse potential, and ENa is the measured sodium channel 
equilibrium potential. The conductance of activation, steady-state fast inactivation 
(h∞) and slow inactivation curves were fitted using the general Boltzmann 
function: I=offset + {amplitude/[1+exp(Vhalf -V)/Slope]}. Slope factors and Vhalf 
(V1/2) were also calculated based on Boltzmann function analysis. V1/2 is the 
voltage at which the current is half maximal. Data are presented as mean ± SE. n 
is presented as the number of the separate experimental cells. The equations 
used for the dose-inhibition relationships for lidocaine and the Nav channels were 
as follows: Sigmoidal dose-response with variable slope: Y= Bottom + (Top -
Bottom)/[ 1 + 10(LogEC50-X)-Hillslope)] (2). Bottom is the Y value at the bottom plateau. 
Top is the Y value at the top plateau. LogEC50 is the X value when the response 
is halfway between Bottom and Top. Hill Slope describes the steepness of the 
curve. Statistical difference was assessed using either student’s unpaired t-test 
or one way ANOVA integrated in the Prism 4 software package. Specifically, for 
action potential duration (APD) comparison, membrane current density 
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comparison, and ramp current density comparison, data was analyzed using un-
paired t-tests with a significance level of 0.05.  
Protein bands were quantified by densitometry using Molecular Analyst 
software (version 1.4; Bio-Rad). The percentage of normalized biotinylated 
protein was compared using un-paired student’s t-test. P < 0.05 was considered 
statistically significant. P < 0.01 was considered statistically very significant. Data 
was presented as mean ± S.E.M (standard error of the mean).  
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III. RESULTS 
 
A. Deletion of F1486 within the intracellular loop between DIII-DIV of  
hNav1.5 reduces peak current density in HEK293 cells and neonatal  
rat cardiomyocytes  
Wild-type (WT) hNav1.5 or the F1486del channel were transiently 
transfected with the auxiliary β1 subunit into HEK293 cells. Electrophysiological 
properties of the channels were investigated using standard whole-cell voltage-
clamp techniques. Remarkably, the initial comparison of current traces from both 
channels revealed striking differences in current amplitude and channel kinetics. 
F1486del channels showed significantly decreased current density compared to 
WT channels (Figure. 10A). The averaged peak current density at -20 mV was 
significantly larger for WT channels (513.1 ± 76.14 pA/pF, n=14) than for 
F1486del channels (100.2 ± 24.13 pA/pF, n=14 p < 0.001, Figure. 10C). Initially, 
this observation was surprising as the IFM motif was previously reported to be 
solely critical for channel inactivation and LQT3 mutations are typically 
associated with gain-of-function, not loss-of-function effects. To verify that the 
decrease in current density was not an artifact that was caused by the 
heterologous expression system, we sought to express the channel in neonatal 
cardiomyocytes. 
 In order to isolate sodium currents generated by recombinant channels in 
myocytes, the hNav1.5 constructs were mutated (C374S) to greatly increase 
their resistance to TTX. Endogenous sodium currents were largely blocked 
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(>95%) by application of 20 μM TTX (Figure 11), allowing isolation and 
characterization of currents generated by the C374S channels.  
We then compared the current density for each type of channel that was 
expressed in the primary cells, and found that in neonatal myocytes the F1486del 
channels still carried less current (Figure 12A and B), as in HEK293 cells. 
cardiomyocytes transfected with the WT channels had an averaged peak current 
density of 385.6 ± 87.7 pA/pF (n=12), while the F1486del channels carried a 
current density of only 117.3 ± 18.9 pA/PF (n=8) (p < 0.05, Figure 12C). The loss 
of function phenotype regarding the peak current density for F1486del channel 
suggests that possible defects in channel trafficking and/or cellular toxicity were 
induced by the mutation. 
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Figure 10. F1486del within the intracellular loop between DIII-DIV of 
hNav1.5 reduced peak current density in HEK293 cells. A. Representative 
sodium current traces recorded from HEK293 cells for WT versus F1486del 
channels elicited using an incremental depolarizing protocol. Both channels were 
co-expressed with human auxiliary β1 subunits. B. Test protocol used for the 
current density measurements is illustrated. The depolarization voltage step is 
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with 5 mV increments. C. Mean current-voltage relationships in response to 50 
ms stimulation pulses from -80 mV to +60 mV (5 mV increments) for WT (n=25, 
closed squares) and F1486del (n=14, closed triangles) channels expressed in 
HEK293 cells.  
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Figure 11. Endogenous sodium currents in neonatal cardiomyocytes were 
blocked by TTX at a final concentration of 20 μM. A. Representative sodium 
current traces recorded from a neonatal cardiomoycyte without the transfection of 
recombinant voltage-gated sodium channels. B. Representative sodium current 
traces from the same cell as in A. After applying 20 μM TTX, the currents carried 
by the endogenous sodium channels were largely blocked.  
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Figure 12. F1486del results in decrease in membrane current density in 
neonatal rat cardiomyocytes. A. Representative sodium current traces 
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recorded from neonatal cardiomyocytes expressing TTX resistant WT channel 
(n=12 for TTXR WT), or TTX resistant F1486del channel (n=8 for TTXR 
F1486del) in the presence of 20 μM TTX. B. Test protocols used for the current 
density measurements; the depolarization voltage step is with a 5 mV increment. 
C. Mean current-voltage relationships for cardiomyocytes ectopically expressing 
each type of channel in response to the voltage stimulation. 
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B. Deletion of F1486 decreases sodium channel surface expression  
in HEK293 cells 
To quantitatively compare the levels of hNav1.5 protein at the cell surface, 
cell surface biotinylation experiments were performed. Since the cysteine and 
lysine residues were confirmed to exist in the extracellular loops, we used EZ-link 
Sulfo-NHS-LC-Biotin reagent to biotinylate the cell surface Nav1.5 protein. 
HEK293 cells expressing the WT or F1486del mutant proteins were incubated 
with the cysteine and lysine specific, cell impermeable EZ-link Sulfo-NHS-LC-
Biotin reagent. Following cell lysate protein solubilization, the biotinylated protein 
was precipitated with streptavidin-agarose beads and subjected to 
electrophoresis and immunoblot reactions with the anti-Nav1.5 specific antibody. 
The non-fractioned aliquot (5%) of the solubilized protein was electrophoresed in 
parallel. The surface expression of β-tubulin was used as a control to indicate if 
there is a cytosolic protein contamination in the reaction. The total blotted β-
tubulin protein was blotted in parallel to determine the fraction of sodium channel 
protein biotinylated by the procedure (Figure 13A). From the western blot 
analysis, surface expression and the total expression level of Nav1.5 were higher 
for WT protein (Figure 13A). The analyzed quantitative results indicate that the 
wild type sodium channel expression at the cell surface was significantly higher 
than the F1486del mutant protein (Figure 13B). We conclude that F1486del 
significantly decrease surface expression of the Nav1.5 protein in HEK293 cells, 
consistent with the data on current density collected using patch-clamp technique.  
 
75 
 
 
Figure 13. Deletion of F1486 decreases sodium channel surface expression 
in HEK293 cells. HEK293 cells expressing WT or F1486del mutant channel 
protein were labeled with sulfo-NHS-LC-biotin. 36-48 h post transfection, 
biotinylated proteins were precipitated with streptavidin-agarose beads. After 
electrophoresis, hNav1.5 proteins were identified by immunoblot analysis using a 
polyclonal rabbit Nav1.5 antibody (ASC-005). A. Surface fraction of Nav1.5 
protein is higher in cells expressing the WT channel protein. Probe for surface β-
tubulin indicates that there is no cytosolic protein contamination for the 
biotinylation experiment. B. The percentage of biotinylated hNav.15 protein was 
determined by normalizing the surface biotinylated protein to the total β-tubulin 
(n=4, performed in quadruplicate). “*” indicates p < 0.05 compared with WT. 
Statistic analysis was performed using un-paired student’s t- test.   
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C. Deletion of F1486 augments late sodium current (late INa) in HEK293 
cells and neonatal rat cardiomyocytes  
In addition to the changes in sodium current density which were observed 
from the sodium current traces using the depolarizing protocol from -80 mV to 
+40 mV (for both WT and F1486del mutant channel), sodium current recorded in 
cells expressing WT channel activated and decayed rapidly (Figure 10A, and 
12A). The inactivation was essentially complete during longer test pulses (Figure 
10A and 12A). However, the mutant channel displays incomplete inactivation 
(Figure10A and 12A). Therefore next we sought to quantify the late sodium 
current by normalizing the current remaining at the end of 200 ms depolarizing 
pulses to the peak amplitude derived from the same depolarizing stimulus. At the 
voltage of -10 mV, there was only 0.67% of the late sodium current remained in 
HEK293 cells expressing WT sodium channels, and only 0.18% late INa left in 
cardiomyocytes ectopically expressing the WT recombinant sodium channels. In 
comparison, cells expressing the F1486del mutant channels had incomplete 
decay of the sodium current. At the end of the 200 ms stimulation pulses, 
approximately 20.69% of the sodium current remaining in HEK293 cells and 19.8% 
late INa remained in cardiomyocytes. Representative traces of late sodium current 
recorded at -10 mV from each type of channel are shown in Figures 14A and 15A. 
At each of the test voltages we studied, the remaining late sodium current was 
significantly higher in cells expressing F1486del mutant channels than WT 
channels (Figure 14B and 15B). This relative amount of late current is 
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substantially higher than that reported with other LQT3 mutations (Wang et al., 
1996; Bankston et al., 2007b), which is from ~0.4%.to less than 5%. 
The marked increase in INa late sodium current by F1486del is consistent 
with the severe clinical phenotype found by Yamamura et al. (2009). We 
hypothesized that the increase in late sodium current should contribute to the 
delayed repolarization of cardiac cellular action potentials.  
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Figure 14. F1486del augments late INa in HEK293 cells. A. Representative 
traces of sodium current recorded at -10 mV from HEK293 cells transfected with 
each gene. The averaged raw data from F1486del mutant and WT channels are 
indicated in the graph. Augmented late INa was shown by normalizing the trace 
recorded from F1486del mutant channels to the trace recorded from WT 
channels, and is labeled “normalized”. B. Protocol used in measuring late INa 
shown in panel A. C. Bar graph indicates the summarized percentage of late INa 
(normalized to the peak current amplitude) in HEK293 cells recorded at each 
tested voltage. “*” represent p < 0.01. F1486del mutant channel (n=12) vs.WT 
channel (n=6).  
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Figure 15. F1486del augments late INa in neonatal rat cardiomyocytes. 
A. Representative traces of the mean sodium current recorded at -10 mV from 
cardiomyocytes expressing each channel in the presence of 20 μM TTX. The 
trace for F1486del and WT channels are labeled respectively. The line indicating 
the normalized data from F1486del channels is labeled in the graph. B. Bar 
graph indicates the averaged late INa recorded from neonatal rat cardiomyocytes 
at each tested voltage in the presence of 20 μM TTX. “*” represent p < 0.01. 
F1486del (n=7) channel vs.WT channel (n=6). 
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D. F1486del does not alter voltage dependence of activation in both  
HEK293 cells and neonatal rat cardiomyocytes 
The location of the deletion site within the Nav1.5 inactivation gate (in the 
linker region between DIII and DIV), and the clinical cardiac phenotype of the 
patient triggered us to further characterize the mutant channel.  
Cells expressing WT SCN5A exhibited rapid activation and inactivation in 
response to a series of depolarizing test pulse from -80 mV to +60 mV, which is 
typical for voltage-gated sodium channels. The F1486del mutant channel, 
however, shows a similar profile of fast activation, but with incomplete 
inactivation throughout the duration of stimulation pulse. The voltage 
dependence of activation for each type of channel was measured using a series 
of test pulses ranging from -80 mV to +60 mV with a 5-mV increment. 
Conductance-voltage (G-V) curve analysis revealed that there was no difference 
in the channel activation profile between these two types of channels (Figure 16A, 
B, and 17). The midpoint of channel activation and the conductance slope factor 
of the activation curve were calculated using Boltzmann function. The 
macroscopic voltage dependence of activation for the WT channel wasn’t 
statistically different from that of the F1486del mutant channel expressed in 
HEK293 cells (Figure 16A, B and Table 5). Again, we observed a similar voltage 
dependence of channel activation profile in cardiomyocytes expressing these two 
types of channel respectively (Figure 17, Table 6). This result is consistent with 
previous results indicating that mutation of any of the amino acids within IFM 
motif does not alter the voltage dependence of channel activation in Xenopus 
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oocytes (West et al., 1992). The similarity in channel activation kinetics suggests 
that this mutation does not directly affect gating charge movement.  
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Figure 16. F1486del does not affect the voltage dependence of Na+ channel 
activation in HEK293 cells. A. Mean steady-state activation curves generated 
under the 50 ms stimulation pulses from -80 mV to +60 mV with 5 mV increments 
for WT (n=14, closed squares) and mutant channels (n=13, open circles) that are 
expressed in HEK293 cells. Data indicate that F1486del does not affect the 
voltage dependence of activation. Both activation curves were fitted with 
Boltzmann function. There is no statistic difference in the parameters for steady-
state activation. B. The I-V relationship analysis for both WT and F1486del 
mutant indicates there is no difference in sodium channel activation, since these 
two curves overlap with each other (n=14 for WT, closed squares; n=13 for 
F1486del, open circles). C. The protocol used to determine the voltage 
dependence of activation.   
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Figure 17. F1486del does not affect the voltage dependence of Na+ channel 
activation in neonatal rat cardiomoycytes. Mean steady-state activation curve 
was generated using the same protocol as in the previous figure. n=12 for TTXR 
WT channel, and n=8 for TTXR F1486del mutant channel. These two activation 
curves overlap and there is no statistical difference for V1/2 between the two 
groups Statistical significance was determined using a Student’s unpaired t-test. 
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Table 5. Voltage-dependent gating parameters for WT and F1486del mutant Na+ 
channels in HEK293 cells 
 Activation  Inactivation 
V1/2, mV k, slope      n    V1/2, mV k, slope    n 
 
Wild type 
 
-41.46±0.85 
 
6.45±0.31 
 
14 
 
 
  -82.94±2.99 
 
9.99±1.56 
 
  11 
F1486del -42.66±0.46 6.92±0.32 13  
 
-65.98±1.74* 
 
8.69±0.81   16 
v1/2, voltage at which the channel is half activated or half inactivated; k, slope 
factor; n, number of cells recorded. The values are presented as mean ± S.E.M. 
Student’s unpaired t-test was used for statistic analysis. “*” represents p < 0.05.  
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Table 6. Voltage-dependent gating parameters for WT and F1486del channels 
expressed in cardiomyoytes 
 Activation  Inactivation 
V1/2, mV k, slope      n     V1/2, mV k, slope    n 
 
Wild type 
 
-14.83±1.58 
 
6.45±0.31 
 
12 
 
 
-71.66±0.03 
 
7.13±1.16 
 
  12 
F1486del -12.02±1.47 6.92±0.32  7  
 
-54.04±0.02* 
 
6.63±0.81    8 
v1/2, voltage at which the channel is half activated or half inactivated; k, slope 
factor; n, number of cells recorded. The values are presented as mean ± S.E.M. 
Student’s unpaired t-test was used for statistic analysis. “*” represents p < 0.05  
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E. F1486del does not alter the time constants for channel deactivation  
in HEK293 cells 
Action potential duration could also be regulated by the rate of 
transition from the open activated state to the close resting state, a gating 
process referred to as “deactivation”. Mediated by the integrated returning of 
the S4 “voltage sensor” to a primed position (Oxford, 1981; Kuo & Bean, 1994; 
Featherstone et al., 1998), deactivation can affect cell excitability (Sheets et 
al., 2007). Based on this idea, we attempted to evaluate the time constant of 
deactivation for both WT and the mutant channel. The analysis for the time 
constant for deactivaton indicated that the F1486del mutant channel takes 
similar time to transition out of the open activated state as the WT channel. 
Therefore, there is no difference in the time constant and rate of deactivation 
between F1486del and WT channels (Figure 18). 
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Figure 18. F1486del does not alter the time constants of channel 
deactivation in HEK293 cells. The upper panel illustrates the protocol used for 
testing channel deactivation time constants in HEK293 cells. Changes in channel 
deactivation for the F1486del channels determined under a range of membrane 
potentials by observing tail current properties. The lower panel indicates there is 
no difference in deactivation between F1486del and WT sodium channels at test 
voltages.   
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F. Multiple biophysical consequences of the F1486del may lead to delayed 
repolarization and APD prolongation  
The IFM motif in a neuronal form of sodium channel Nav1.2 has been 
demonstrated to be critical for channel inactivation. Triple mutation of these three 
amino acids to glutamine (Q) in Nav1.2 has been shown to slow the rate of 
channel inactivation in Xenopus oocytes (West et al., 1992). In our study, deletion 
of F1486 increased the persistent late sodium current. Based on this observation, 
we next tested the hypothesis that deletion of amino acid of Phe on Nav1.5 could 
alter the voltage dependence of channel inactivation. In our experimental system 
using both HEK293 cells and cardiomyocytes, we observed a rightward shift of 
the steady-state fast inactivation curve for the mutant channel (Figure 19A), 
which suggests that inactivation was disrupted by deletion of F1486. When 
expressed in HEK293 cells, the F1486del mutation caused a +16.96 mV 
depolarizing shift in the V1/2 of channel availability (WT: V1/2= -82.94 ± 2.99 mV, 
n=14 and F1486del: V1/2= -65.98 ± 1.74, n=13; p < 0.01, Student’s unpaired t-test) 
with little or almost no change in the slope factor of the fitted Boltzmann current-
voltage relationships (WT: k slope = 6.45 ± 0.31, n=14 and F1486del k slope = 
6.92 ± 0.32, n=13; p > 0.05, Student’s unpaired t-test). In cardiomyocytes, the 
F1486del mutant channel caused a +17.13 mV depolarizing shift in the V1/2 of 
channel availability and a statistical difference in the slope factor (Figure 21A, 
Table 6). The V1/2 of inactivation is defined as the voltage at which 50% of the 
channel population has transitioned to a non-conducting inactivated state. The 
fraction of the available channels was almost zero when the prepulse potential 
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was close to and above -40 mV for WT channels (Figure 21A, and 23A). By 
contrast, nearly 20% of the mutant channels were still available when the cells 
were prepulsed to -40 mV (Figure 19A, and 21A).  
Overall, the F1486del mutant channel has a clear defect in transition to 
the closed inactivated state. The marked increase in V1/2 toward positive 
potentials, the rightward shift of the inactivation curve, and the incomplete 
inactivation of the mutant channel are consistent with increased mutant channel 
activity, which may explain the prolongation of action potentials.  
Destabilization of the inactivated state can affect the region in the voltage-
conduction relationship curve where steady-state channel activation and 
inactivation overlap. This destabilization will result in an increased probability of 
channel re-opening at the membrane potential close to the resting potential. 
Therefore, the destabilization can develop persistent “window currents” (Hodgkin 
& Huxley, 1952b). The window current is thought to result from the opening of 
non-inactivated sodium current, so called “persistent INa”. The depolarizing shift 
of the inactivation resulted in a bigger window current when the F186del mutant 
channel is expressed in both HEK293 cells and cardiomyocytes (Figure 20, and 
22).  
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Figure 19. F1486del causes a depolarizing shift in the voltage dependence 
of inactivation in HEK293 cells. A. The steady-state fast inactivation curve for 
F1486del channels (open circles, n=16) is shifted toward more positive potentials 
compared to the curve for wild type channel (filled squares, n=11). The channels 
that remain available after each inactivating prepulse were evaluated by the peak 
current amplitude produced during a test pulse to -10 mV for 20 ms. B. The 
protocol that was used to study steady-state inactivation of sodium channels is 
illustrated. Cells were held at -100 mV and stepped to an inactivating repulse (-
150 mV to -10 mV) for 500 ms.  
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Figure 20. F1486del increases window sodium current in HEK293 cells. The 
window current is represented by the area which is created by the overlap of 
steady-state activation and steady-state fast inactivation curves. A. The shaded 
region represents the window current generated by WT hNav1.5 channels. Since 
the activation curves for both WT (n=14) and F1486del (n=13) channels overlap 
with each other, the shaded region plus the blank area (underneath both the 
activation curve and the inactivation curve for F1486del) represent the window 
current generated by F1486del sodium channels, which is indicated by the arrow 
line. Window current measurement indicates that F1486del channels expressed 
in HEK293 cells conduct more non-inactivating sodium current. N=11 for WT 
steady-state inactivation curve, and n=16 for F1486del steady-state inactivation 
curve. B, and C. Protocols used to analyze the steady-state window current are 
illustrated.   
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Figure 21. F1486del causes a depolarizing shift in the voltage dependence 
of inactivation in neonatal rat cardiomyocytes. A. The F1486del causes a 
+17.13 mV depolarizing shift in the steady-state availability curve. Data shown for 
TTXR WT (closed squares, n=15) and TTXR F1486del (open circles, n=18) 
channels. B. The protocol that was used for the study of steady-state inactivation 
of sodium channels is illustrated.  
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Figure 22. F1486del causes an augmentation of window sodium current in 
neonatal rat cardiomyocytes. A. The window current is indicated by the 
overlapping area covered by the steady-state activation and the steady-state 
inactivation curves. The shaded region represents the window current generated 
by TTXR WT hNav1.5 channels. Since the activation curves for both TTXR WT 
(closed squares, n=12) and TTXR F1486del (open triangles, n=7) channels 
overlap with each other, the shaded region plus the blank region (underneath 
both the activation curve and the inactivation curve for TTXR F1486del) 
represent the window current generated by TTXR F1486del hNav1.5 channels, 
which is indicated by the arrow line. Data indicates that TTXR F1486del channels 
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carry a significant larger non-inactivating window current. N=15 for TTXR WT 
steady-state inactivation curve, and n=18 for TTXR F1486del steady-state 
inactivation curve. B, and C. Protocols used to study the steady-state window 
current are illustrated.  
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G. F1486del leads to the increased time constants for recovery from  
inactivation 
Since inactivation is not the only factor that can alter the action potential 
duration, we further tested for the effects of the F1486del on the time constants 
of recovery from inactivation. The time constants of recovery from inactivation 
was investigated using a 100 ms conditioning pulse -10 mV to induce channel 
inactivation followed by a recovery pulse after returning to -120 mV for various 
durations and then a test pulse to -10 mV to assess the fraction of channels that 
had recovered from inactivation. Data from these experiments were fitted by the 
two-exponential function. The averaged time constant for channels to recover 
from inactivation was significantly different between these two groups. F1486del 
channels took a significantly longer time to recover from inactivation (Tau-120 = 
70.20 ± 14.55, n=7), while the WT channels recover much quicker from 
inactivation (Tau-120 = 14.58 ± 1.38, n=4; p < 0.01, student’s unpaired t-test). The 
F1486del slows the speed by which sodium channels recover from inactivation to 
the available (resting, closed) state. This result indicates that the F1486del 
mutant channel undergoes a slower transition process from the inactivated state 
to the resting state. The IFM motif forms a hydrophobic particle which binds to its 
receptor, the inactivation gate. We hypothesized that by deleting one 
hydrophobic amino acid, F1486, the hydrophobic strength is decreased thus the 
particle difficult to bind to or easy to come off from its receptor. Surprisingly, the 
channel paradoxically shows impaired inactivation as well as slower recovery 
from inactivation.  
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H. F1486del produces augmented ramp current in both HEK293 cells and 
neonatal rat cardiomyocytes  
The relatively slow transitions of sodium channels to closed-state 
inactivation are considered to produce ramp current in response to slow 
depolarizing voltage ramps at hyperpolarized potentials close to resting 
membrane potential (Cummins et al., 1998; Rush et al., 2006). Furthermore, the 
ramp current has been thought to contribute to action potential firing threshold 
and cellular excitability (Crill, 1996). Therefore, we sought to examine ramp 
currents in cells expressing either WT or F1486del channels. A broad duration of 
positive ramp voltages (0.28 mV/ms) was given to HEK293 cells expressing 
either WT or mutant channels. In response to the positive voltages, WT channels 
carry inward sodium current, but this conduction was only sustained over a 
narrow voltage range. By contrast, the F1486del mutant channels conduct over a 
broader range of voltages. A significant increase in the current amplitude of the 
ramp currents elicited especially at more depolarized potentials for the mutant 
F1486del channels was observed (Figure 23, 24). The ramp current generated in 
response to 500 ms slow depolarizing test pulse by the mutant channel was 
increased by 86.88% compared to the WT channel. There was a significant 
difference between these two types of channels regarding the averaged 
normalized ramp current (normalized to the peak current) (Figure 23A, 24A). In 
addition, the mutant channels showed delayed inactivation toward positive 
potential stimuli and never completely inactivated at the end of the voltage ramp 
when compared to WT channels (Figure 23A, 24A). The comparison of the 
99 
 
averaged normalized ramp current is shown in Figure 23B, and 24B. The 
characteristics for the ramp current generated by the F1486del mutant channel 
revealed an impaired transition to a non-conducting state. This increase in ramp 
current might reflect similar mechanisms that contribute to the increase of late 
current.  
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Figure 23. F1486del increases ramp current in HEK293 cells. A. Averaged 
normalized WT (n=10) and F1486del (n=10) ramp currents in response to a ramp 
protocol of 500 ms with a voltage from -100 mV to +40 mV. Data demonstrate 
that F1486del enhances inward sodium current within a broad range of 
membrane voltage. B. Bar graph interpretation of averaged ramp current as a 
percentage of peak transient current during the slow depolarizing ramp stimulus 
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for all channels examined in this study. (n=10 for WT, n=10 for F1486del). Ramp 
current amplitude is presented as a percentage of the peak transient current 
elicited with a standard I-V protocol. Unpaired student’s t-test was used for data 
analysis. “*” indicates p < 0.001.  
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Figure 24. F1486del causes an augmentation of ramp current in neonatal 
rat cardiomyocytes.  A. Averaged normalized ramp current elicited in response 
to a slow depolarizing stimulus for TTX-R WT (n=6) and F1486del (n=4) channels 
from -100 mV to +40 mV during 500 ms with a holding potential of -100mV. Data 
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demonstrate TTX-R F1486del enhances inward sodium ramp current. Ramp 
current was normalized to the peak current amplitude elicited with a standard I-V 
protocol. B. Bar graph interpretation of percentage peak current during the slow 
depolarizing ramp stimulus for all channels examined in this study. (n=6 for TTX-
R WT, n=4 for TTX-R F1486del). Ramp current amplitude is presented as a 
percentage of the peak transient current elicited with a standard I-V protocol. 
Unpaired student’s t-test was used in statistical analysis. “*” indicates p < 0.001.  
  
104 
 
I. F1486del on hNav.15 prolongs APD and generates EADs in neonatal  
neonatal rat cardiomyocytes  
As the slow inactivating component of sodium current, late INa is a 
depolarizing current that increases the duration of the ventricular action potential 
(Kiyosue & Arita, 1989; Bennett et al., 1995). In our studies, we observed the 
augmentation of sustained late INa by the F1486del mutation. The proband 
identified by Yamamura and his colleagues presented a severe cardiac 
arrhythmia with an extreme prolonged corrected QT interval (as long as 860 ms). 
Based on our experimental results, we hypothesized that the LQTs manifested in 
the patient was caused by the APD prolongation, which was subsequent to 
increased late INa. To further explore the functional consequence of deleting 
F1486, we chose to use primary neonatal rat cardiomyocytes as an expression 
system to study action potential profiles. Since the proband carried the 
heterologous deletion of hNav1.5 F1486 on one allele, we chose to study the 
function of the mutant channel in the presence of the endogenous sodium 
channel. Therefore, no TTX was added in this set of experiments. Representative 
action potential traces are shown in Figure 27A. Cardiomyocytes carrying the 
heterologously expressed WT sodium channel had an averaged APD of 88.9 ms, 
which is typical for neonatal cardiomyocytes (Figure 25A, and 25B). In contrast, 
cells expressing the F1486del mutant channel had a very significant prolongation 
of the action potential duration (Figure 25A and B, averaged APD 1001.0 ms, p < 
0.0001 compared to WT). In this study, the early phases of the action potential 
repolarization was indicated by APD30, while the final steady-state repolarization 
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phase of the action potential repolarization was indicated by APD50, APD80 and 
APD90. During each stage of the action potential repolarization phase, there were 
significant differences between these two groups (Figure 25C). We also observed 
the decrease in sodium current density and increase in late sodium current in 
cardiomyocytes expressing the mutant channel which were consistent with our 
findings using HEK293 cells. An increase in late INa has been shown to be 
followed by sequential appearance of EADs (Song et al., 2008), early 
afterdepolarizations that usually happen during the early phase of the action 
potential repolarization. In our experimental system with rat cardiomyocytes, we 
were interested in exploring whether increased late INa induced by the channel 
mutation would facilitate occurrence of EADs, which are commonly associated 
with bradyarrhythmia-triggered arrhythmic activity (Clancy et al., 2002). In 
cardiomyocytes expressing the mutant recombinant channel, we observed a 
series of spontaneous EADs in 33.3% of the cells we studied (4/12) (Figure 26). 
In contrast, cells expressing the WT recombinant channel mostly carry the 
normal profile of the action potential, with no observed EADs (0/22) (Figure 26). 
We predict that the APD prolongation, as a result of increased late INa, causes 
the occurrence of EADs, and leads to the subsequent bradycardia-induced 
arrhythmia. We also predict that the APD prolongation is due to the deficit in 
inactivation.  
106 
 
 
 
Figure 25. hNav1.5 F1486del prolongs APD in neonatal rat cardiomyocytes. 
A. Representative traces for neonatal rat cardiomyocytes expressing either WT 
or F1486del channels. B. Averaged data analysis for the APD measurement. 
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Cardiomyocytes expressing the WT recombinant channel have an averaged APD 
of 88.87 ± 28.63 ms (n=12); whereas the averaged APD for cells expressing the 
F1486del channel is 1001 ± 167.1 (n=11, * p < 0.0001). Data was analyzed using 
Student’s unpaired t-test. C. Averaged APDs (APD at 20%, 30%, 50%, 70%, and 
90% repolarization (APD20, APD30, APD50, APD70, and APD90, respectively) 
indicate that cells expressing the mutant channels take significantly longer time 
to repolarize to the resting membrane potential. Data was shown as mean ± SE. 
n=15 for WT, n=7 for F1486del and n=5 for non-transfected cells. “*” p < 0.001, 
cells expressing F1486del channel vs. the other two types of channel. There is 
no statistical significance in APD analysis between cells expressing WT 
recombinant channels and non-transfected cells expressing endogenous sodium 
channels. Data was analyzed by one way ANOVA plus Bonferroni posthoc test.  
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Figure 26. Cardiomyocytes expressing F1486del mutant channels 
presented with spontaneous EADs. A. A representative recording from a 
neonatal cardiomyocyte expressing the WT channels. One single current 
injection was given to the cell for 2.5 ms. The APD was within the normal range. 
There was no EAD observed. B, and C. Representative traces from two 
individual cells expressing the F1486del channels. Cells were also injected with 
one single current injection for 2.5 ms. Cells present not only prolonged APD, but 
prominent EADs, which may lead to LQTs and further trigger electrical activity.  
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J. F1486del attenuates the response to antiarrhythmic drug lidocaine in  
HEK293 cells 
The poor response of the infant patient carrying mutant F1486del 
channels to therapeutic treatment with lidocaine (Yamamura et al., 2009) and the 
location of the mutation site led us to determine: whether deletion of F1486 could 
modify the sensitivity of the sodium channel to the antiarrhythmic drug lidocaine? 
As a local anesthetic and antiarrhythmic drug, lidocaine interferes with 
impulse conduction by binding to the inner pore of voltage-gated sodium 
channels to block the current (Hille, 2001). Experimental evidence suggests that 
local anesthetics can bind to the sodium channel in resting, open and inactivated 
states, but preferentially binds to the open and/or inactivated VGSCs (Hille, 1977; 
Hondeghem & Katzung, 1977; Yeh, 1978; Bean et al., 1983). In order to examine 
the ability of lidocaine to inhibit channels in the resting state, cells expressing 
Nav1.5 channels were held at -120 mV for 10s (to allow all channels to move to 
the resting state) and then depolarized to 0 mV for 20 ms to elicit the current. 
Different concentrations of lidocaine were applied to the cells to test its inhibitory 
effect on sodium channel. Peak current amplitude was evaluated before and after 
application of lidocaine hydrochloride (10-3000 μM; n = 3-5). Data points from 
each concentration that we studied were fitted to a dose-response curve (Figure 
27A). The IC50 (estimated by fitting the data points to a dose-response curve) of 
WT channel was 96.21 μM, and was 525.50 μM for mutant channel, suggesting 
that the F1486del decreases the sensitivity of the channel to lidocaine (Table 7). 
Representative traces recorded when cells expressing the WT and F1486del 
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mutant channels were treated with 100 μM lidocaine are shown in Figure 28. 
Since the location of the F1486 site is essential for steady-state inactivation, we 
then compared the inhibitory effects of lidocaine on the inactivated channels for 
both WT and F1486del mutants. The ability of lidocaine to interact with 
inactivated channels was examined by holding cells expressing Nav1.5 channels 
at -50 mV for 10s (to allow channels to move to inactivated states) and then 
stepping the voltage to -120 mV for 100 ms (channels without drug bound would 
recover from fast inactivation). Finally, the cells were depolarized to 0 mV for 20 
ms to elicit currents and measure channel availability. Peak current was also 
measured before and after application of lidocaine (10-1000 μM; n = 3-6). Fits to 
the dose-response curve revealed that the IC50 for lidocaine on inactivated WT 
Nav1.5 channels is 17.12 μM (Figure 29, Table 7). Although WT channels did 
respond to lidocaine hydrochloride in a dose-response manner in the inactivated 
state, the F1486del mutant channel does not response to lidocaine in the 
inactivated state, even at 1 mM  drug concentration (Figure 29, 30). Therefore, it 
is possible that deletion of F1486del induces a channel conformational change 
that prevents lidocaine from binding. Putting these together, we hypothesize that 
the poor response of the patient to lidocaine is caused by the deletion of F1486 
on Nav1.5.  
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Figure 27. Dose-response curve for the inhibitory effect of lidocaine on 
hNav1.5 WT and F1486del channels in the resting state. A. hNav1.5 WT or 
F1486del mutant channels are expressed in HEK293 cells. F1486del causes a 
rightward shift of the concentration-response curve for the F1486del mutant 
channel, which indicates that deletion of F1486 attenuates the pharmacological 
effect of lidocaine on the sodium channel in the resting state. Data are presented 
as averaged normalized peak current ± S.E.M (* p < 0.05, ** p < 0.01). The peak 
current amplitude after drug treatment was normalized to that before drug 
treatment. Data were fitted with Sigmoidal dose-response curve with variable 
slopes (R2 = 0.97 for F1486del, R2=0.86 for WT). 3-8 individual recordings were 
collected for each dose. B. Protocol used for testing the inhibitory effects of 
lidocaine on sodium channels in the resting state is illustrated.   
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Figure 28. Deletion of F1486 attenuates the effect of 100 μM lidocaine on 
sodium channels in the resting state. Representative traces recorded from 
HEK293 cells expressing the WT and F1486del mutant channels in the presence 
of 100 μM lidocaine under the protocol for testing the inhibitory effect of lidocaine 
on resting-state channels. 100 μM lidocaine has a differential effect on WT and 
F1486del mutant hNav.15 channels. The protocol used in this study is shown in 
the lower panel.  
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Figure 29. Dose-response curve for the inhibitory effect of lidocaine on 
inactivated hNav1.5 channels. A. The peak current amplitude after drug 
treatment was normalized to that before drug treatment. Only the data collected 
from WT channel can be fitted with Sigmoidal dose-response curve (R2 = 0.92, 
IC50 = 17.12 μM). Data are presented as averaged normalized peak current ± 
S.E.M (* p < 0.01, ** p < 0.001).The dotted line was drawn to manually connect 
the F1486del data point and serves as a guide to visualize the data. 3-8 
individual recordings were collected for each dose. B. Protocol used for testing 
the inhibitory effects of lidocaine on sodium channels in the inactivated state is 
illustrated.   
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Figure 30. F1486del reduces the effect of lidocaine on sodium channels in 
the inactivated state. The upper panel shows representative traces recorded 
when cells expressing the WT and F1486del channels were treated with 300 μM 
lidocaine, and tested for the inhibitory effect of lidocaine on inactivated channels. 
Voltage protocol for testing current amplitude generated after drug binding to the 
inactivated channel is diagramed in the lower panel. 
  
115 
 
Table 7. Summary of IC50 values estimated for lidocaine inhibition of hNav1.5 
channels in different states 
IC50 (μM) Resting State Inactivated State 
WT 96.21 17.12 
F1486del 525.50 N/A 
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SUPPLEMENTAL RESULTS 
 
K. Sodium channel mutation G1481E within the intracellular loop between  
DIII-DIV of hNav1.5 increases peak current density in HEK293 cells  
The location of G1481 is similar to the F1486 since both of these amino 
acids are located in the intracellular loop between DIII and DIV. Previously, it was 
shown that specific mutations within intracellular loop III are associated with 
LQT3 syndrome (Bankston et al., 2007b; Ruan et al., 2010). In a large group of 
cohort studies, a large cohort of consecutive, unrelated patients referred for long-
QT syndrome were screened for mutations of LQTs related genes by Mayo Clinic 
from August 1997 to July 2004 (Tester et al., 2005). A polymorphism was found at 
nucleotide 4442 where a G to A mutation was observed in a patient with LQT3. 
This change in nucleotide generates a G1481E mutation. Five amino acids 
upstream of F1486, the G1481E might be able to alter the electrophysiological 
function of hNav1.5, and lead to LQT3 syndromes. Thus, the hypothesis for 
studies on G1481E was formed: G1481E mutation on hNav1.5 could affect the 
electrophysiological function of cardiac sodium channel hNav1.5, and lead to 
LQT3 syndromes. Based on this hypothesis, several electrophysiological 
parameters of hNav1.5 G1481E were fully characterized. For this study, the 
expression system utilized is the HEK293 cell line. Transient transfection of 
sodium channel α subunit, β1 subunit and EGFP were performed. First of all, the 
current density was investigated to explore if there is any change in the current 
density when G1481 is mutated to glutamine. Unlike the F1486del mutation 
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channel, G1481E mutation increases the peak current density (Figure 31). So far, 
the exact mechanism underlying this increase is unknown.   
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Figure 31. Sodium channel mutation G1481E within the intracellular loop 
between DIII-DIV of hNav1.5 increases peak current density in HEK293 cells. 
A. Mean current-voltage relationships recorded in response to 50 ms stimulation 
pulse from -80 mV to +60 mV (5 mV increment) for WT (n=14, closed squares) 
and G1481E (n=7, closed circles) mutant channels expressed in HEK293 cells.  
B. Test protocols used for the current density measurements. The depolarization 
voltage step is with 5 mV increment. 
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L. G1481E mutation causes a leftward shift of the steady-state activation  
curve in HEK293 cells  
Sodium channel activation profile was also investigated using a 
depolarization protocol from -80 mV to +40 mV with a 5 mV increment. Peak 
current amplitude under each voltage was measured, and normalized to the 
maximum peak current amplitude. The normalized fraction of current was then 
correlated with the membrane voltage to generate a current-voltage relationship 
curve, which was then fitted using the Boltzmann function. The activation curve 
of G1481E hNav1.5 mutation is shifted to the left as compared to that of WT 
hNav1.5, which suggests that the G1486 mutation causes the channel to activate 
at a more negative potential (Figure 32). The V1/2 (voltage at which channel is 
half activated) value of the mutant channel is more negative, although there is no 
statistical difference in k slope of channel inactivation. Overall, the G1481E 
mutation increases the percentage of sodium current that is activated at a broad 
range of membrane potentials, and induces the channel activation at a more 
negative membrane potential. The left-ward shift of the activation curve may 
explain why the patient carrying the G1481E mutation has LQT3 syndrome. A 
similar observation was made on steady-state activation in LQT3-causing mutant 
channel (Horne et al., 2010).  
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Figure 32. G1481E mutation causes a leftward shift of the steady-state 
activation in HEK293 cells. This figure shows the mean steady-state activation 
curves generated under the 50 ms stimulation pulses from -80 mV to +60 mV 
with 5 mV increments for WT (n=18, open circles) and G1481E mutant channels 
(n=14, closed triangles) that are expressed in HEK293 cells. Data indicate that 
G1481E mutation shifts the voltage dependence of activation to the left. Both 
activation curves were fitted using the Boltzmann function. The leftward shift of 
the activation curve means there are more channels available as compared to 
the WT. The panel below illustrates the protocol that was used to study the 
activation profile.  
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M. The G1481E mutation does not affect sodium channel steady-state fast  
 inactivation  
The intracellular loop III within domain III and IV has been 
demonstrated to be critical for channel inactivation. In our study and West’s 
study (West et al., 1992), F1486 was found to be critical for channel 
inactivation and augmentation of late INa. G1481 is five amino acids upstream 
of F1486, and mutation of G1481 to E was found to be associated with long-
QT syndrome. Based on these facts, we hypothesized that the G1481E 
mutation would lead to the disruption of sodium channel inactivation and lead 
to LQTs. In our experimental system using HEK293 cells, we didn’t observe 
any change in inactivation parameters such as V1/2 and k slope when we 
compare the WT channel with the G1481E mutant channel (Figure 33), which 
suggests that the inactivation was not affected or disrupted by G1481E 
mutation. When expressed in HEK293 cells, the G1481E mutation channel 
has a V1/2 of -83.60 mV (n=18), k slope of 7.0. The WT channel has a V1/2 of -
83.15 mV, and k slope of 8.6 (n=15). There are no statistical changes in these 
two parameters (p > 0.05). The V1/2 of inactivation is defined as the voltage at 
which 50% of the channel population has transitioned to a non-conducting 
inactivated state. The above mentioned observation for both channel types 
suggests that mutation of G1481E does not affect sodium channel 
inactivation.  
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Figure 33. G1481E mutation does not affect sodium channel steady-state 
fast inactivation in HEK293 cells. A. The steady-state fast inactivation curve for 
G1481E mutant channels (closed squares, n=18) is not significantly shifted but it 
is overlapped with the curve for WT channel (closed triangles, n=15). The 
channels that remain available after each inactivating prepulse were evaluated 
by the peak current amplitude produced during a test pulse to -10 mV for 20 ms. 
B. Illustrates the protocol that was used for to study steady sate inactivation of 
sodium channels. Cells were held at -100 mV and stepped to an inactivating 
prepulse (from -150 mV to -10 mV) for 500 ms.  
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N. Sodium channel G1481E mutation does not affect late INa 
LQT3 syndrome is associated with sodium channel gain-of-function 
mutations, which is typically presented as the increase in late sodium current. 
The fundamental basis for our studies on G1481E mutation is that this mutation 
was found to be correlated with the LQT3 syndrome in the retrospective clinical 
case study. It has been found in some other studies that sudden infant death and 
LQT3-causing mutations increases late INa (Bankston et al., 2007a). Therefore, 
we hypothesized that G1481E mutation could cause increase in late sodium 
current, and lead to LQT3 syndrome. Based on this hypothesis, we measured 
remaining late INa at the end of a 200 ms depolarizing pulse under a series of 
voltages. The amplitude of late INa was normalized to each peak current 
amplitude. The summarized data is shown in Figure 34.  
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Figure 34. G1481E mutation does not affect late INa. Bar graph indicates the 
summarized percentage of late INa (normalized to the peak current amplitude) in 
HEK293 cells recorded at each tested voltage. There is no statistical difference 
between WT (n=18) and G1481E mutant channels (n=15).  
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O. The G1481E mutation enhances window current  
Based on the fact that patients carrying this mutation were proposed to be 
correlated with the LQT3, we decided to take further look at this mutation. The 
G1481E mutation causes the leftward depolarizing shift of the steady-state 
activation curve, but no change in the steady-state inactivation curve. Therefore, 
the averaged steady-state window currents were analyzed for both WT and 
G1481E channels. It was found that the G1481E mutation resulted in an increase 
in non-inactivating window current (Figure 35A), which could lead to APD 
prolongation and cause LQT3 in patients. 
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Figure 35. The G1481E mutation increases sodium channel window current 
in HEK293 cells. The window current is represented by the area which is 
created by the overlap of steady-state activation and steady-state fast 
inactivation curves. A. The shaded region represents the window current 
generated by WT hNav1.5 channels (n=9 for activation curve, n=11 for 
inactivation curve). The shaded region plus the blank area (underneath both the 
activation curve and the inactivation curve for G1481E) represent the window 
current generated by G1481El mutant channels (n=11 for steady-state activation 
curve, n=10 for steady-state inactivation curve). Window current measurement 
indicates that G1481E mutant channels conduct more non-inactivating sodium 
current. B, and C. Protocols used to analyze the window current are illustrated.   
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P. The G1481E mutation does not affect the slow inactivation  
In addition to fast inactivation, there is another type of channel inactivation 
which is termed “slow inactivation”. Development and recovery occur over the 
second to minute time scale for the “slow inactivation”. It was proposed that the 
ionic conductance decrease during a prolonged depolarization of several 
seconds is due to the slow inactivation process (Hille, 2001; Ulbricht, 2005). The 
kinetic analysis of steady-state activation and potential interactions between 
activation and slow inactivation suggested that slow inactivation might be 
coupled to the activation voltage sensors (Ruben et al., 1992). It was 
demonstrated that mutation of phenylalanine (Phe, F) within the IFM motif in the 
sodium channel intracellular loop between DIII and DIV affects the steady-state 
fast inactivation but not slow inactivation regarding the study on Nav1.4 sodium 
channel (Cummins & Sigworth, 1996). As stated above, VGSCs can transit to an 
inactivation state called “slow inactivation”, which develops slowly and recover 
slowly (Vilin & Ruben, 2001). Certain mutations of skeletal muscle VGSCs that 
affect the channel availability due to defect in slow inactivation can lead to 
increased cellular excitability (Cummins & Sigworth, 1996). Since it was 
postulated that G1481E is associated with LQT3 syndrome, it is of importance to 
investigate if this mutation affects the voltage dependence of slow inactivation. 
An extended conditioning pulse was designed, after which a brief hyperpolarizing 
pulse (100 ms) was given to the cells to allow the channels to recover from fast 
inactivation. Then, a test depolarization pulse was given to the cell to test the 
fraction of the available channels (Figure 36). Both WT and G1481E mutant 
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channel availability curves were fit with a Boltzmann function. There was no 
notable alteration in the fraction of available channel for G1481E mutant, as 
compared to the WT hNav.1 channel. This result suggests that the LQTs which 
were identified in the patient is not related to slow inactivation.  
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Figure 36. G1481E mutation does not affect the slow inactivation. WT and 
G1481E mutant sodium channels were tested in this study. To study slow 
inactivation, extended conditioning pulse ranging from -150 mV to +10 mV for 10 
seconds were given to the cells. Cells were then applied with a brief 
hyperpolarized pulse to -100 mV to allow rapid recovery of fast inactivated 
channels before testing for the fraction of available channels for 20 ms at +10 mV. 
Both curves were fit with a Boltzmann function. The over-lapped curves indicate 
that there is no difference in slow inactivation. 
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IV. DISCUSSION 
 
A. Overview of the dissertation research  
As an inherited cardiac disorder, congenital LQTs is characterized by the 
prolongation of the QT interval. Patients with LQTs are susceptible to developing 
ventricular tachycardia (VT).  
The cardiac voltage-gated sodium channel Nav1.5 is critical for the 
initiation and propagation of the action potential throughout the heart. Mutations 
of SCN5A are now considered to be associated with a number of cardiac 
diseases such as LQT3, Brugada syndrome, atrial fibrillation, and sudden infant 
death syndrome (Chen et al., 1998; Wang et al., 2007; Makiyama et al., 2008). 
Since the first identification of the sodium channel mutation in a family with LQT 
history, about 80 SCN5A mutations have been reported to cause LQT3 (Inherited 
Arrhythmias Database). These studies have advanced our knowledge of the 
roles that sodium channel plays in cardiac function.  
Yamamura and colleagues identified an infant patient with severe cardiac 
arrhythmia carrying a heterologous F1486 deletion (Yamamura et al., 2009). 
Their ECG studies on this patient indicated prolonged QT interval, 2:1 atria-
ventricular block, and polymorphic VT. Surprisingly, the patient’s VT was 
refractory to intravenous administration of lidocaine. We hypothesized that the 
F1486del of Nav1.5 would alter the sodium channel function, and therefore 
prolong the action potential duration, which would subsequently lead to cardiac 
     2C 
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arrhythmia. We also speculated that the decreased sensitivity to antiarrhythmic 
drug lidocaine resulted from the deletion of F1486.  
In the current study, we extensively characterized biophysical properties of 
the mutant sodium channel with F1486del within the intracellular loop between 
DIII and DIV. We found a loss-of-function alteration of current density and a 
series of gain-of-function changes. Ultimately, these alterations lead to the APD 
prolongation and lead to EADs in the infant patient.  
B. Voltage-clamp studies on the F1486del channel 
This mutation site is within the IFM motif which was required for 
inactivation (Vassilev et al., 1988; Stuhmer et al., 1989; Patton et al., 1992). In 
our study, using both the HEK293 cell line and neonatal rat cardiomyocytes as 
expression systems, we consistently found that cells expressing F1486del 
mutant channels had reduced current density compared to cells expressing WT 
channels. This is a sodium channel loss-of-function phenotype. Although the 
mechanism is not clear, one possibility is that the decreased current density 
reflects from a deficiency in channel trafficking. The SCN5A F1473S mutation, 
within the same intracellular loop as F1486del, has been identified to cause a 
channel trafficking defect (Ruan et al., 2010).  
Sodium current has a slow inactivating persistent component, which is 
called late sodium current (late INa). In rat cardiomyocytes, persistent late INa 
usually has a magnitude of less than 1% of the size of peak transient sodium 
current (Saint et al., 1992). As an inward depolarizing current, late INa can 
increase the duration of the ventricular action potential in cardiomyocytes. 
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Increases in late INa can also facilitate the onset of EADs and cause sustained 
triggered activity (Song et al., 2008). Certain mutations of Nav1.5 associated with 
LQTs and sudden infant death have been shown to increase late sodium current 
when these mutants were expressed in HEK293 cells (Bankston et al., 2007b; 
Ruan et al., 2010). To determine to what extent the F1486del could affect the late 
sodium current, we chose to use a step depolarizing pulse lasting for 200 ms. 
The percentage of late sodium current remaining at 200 ms for WT channel was 
less than 1% percent, consistent with previous findings (Saint et al., 1992). Our 
study clearly demonstrates a significant increase of late INa in cells expressing 
the F1486del mutant channels, which may explain why the infant patient carrying 
this deletion had LQTs and subsequent incessant tachycardia and reduced 
cardiac function. The remarkable effect of the F1486del is an increase in late 
sodium current to ~20% of the peak transient current. It is important to note that 
this increase of late INa is substantially greater than that typically observed with 
other LQT3 mutations. For example, the ∆KPQ mutation only increases the late 
current to ~4% of the peak transient current (An et al., 1996). 
Inactivation is mediated by the inactivation gate (loop region between DIII 
and DIV) and the intracellular C-terminal domain (Vassilev et al., 1988; Kass, 
2006). Mutations associated with LQT3 and sudden infant death generally disrupt 
the voltage-dependent transition to the inactivated state. In our study, the 
F1486del caused a rightward depolarizing shift of the steady-state inactivation, 
suggesting that deletion of F1486 can possibly destabilize the inactivated 
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channel configuration and increase the percentage of channels that retain the 
capability to be activated and stay in the open state (Wang et al., 1996).  
The analysis for I-V relationship and activation curve demonstrates that 
the deletion of F1486 does not affect steady-state fast activation and these data 
are in accordance with previous findings demonstrating that the activation 
kinetics are not affected by other mutations within this region (Vassilev et al., 
1988; Bankston et al., 2007b).  
The process of a voltage-gated channel to transit from open activated 
state back to closed state before the channel goes into inactivation state is 
defined as deactivation. The time constant for deactivation is one of the factors 
that determine cell excitability (Featherstone et al., 1998). Our data show that the 
time constants for the F1486del channel is similar to that for the WT channel.  
The data from time constant analysis for mutant channel recovery from 
inactivation seems contradictory with the fact that the patient has action potential 
prolongation, since a number of SCN5A mutation associated with LQT3 have 
been presented with decreased Tau value for recovery from inactivation (Wang et 
al., 2007). The observation on the time constants for the recovery from 
inactivation suggests that once the channel overcomes the energy barrier and 
goes to the inactivated state, it is difficult for the channel to transition out of the 
open inactivated state.  
C. Therapeutic outcomes of lidocaine on F186del channels  
Lidocaine, with a tertiary amine structure, is widely used as an 
antiarrhythmic drug. We found that lidocaine has a significantly lower IC50 for 
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resting WT Nav1.5 channels than the mutant channels. Lidocaine hydrochloride 
is more potent on inhibiting inactivated WT sodium channels, which is in 
accordance with the previous findings that lidocaine preferentially binds to the 
sodium channel in the inactivated state, and then inhibits the channel 
(Butterworth & Strichartz, 1990; Ragsdale et al., 1996). Interestingly, the ∆KPQ 
mutant channel was not less sensitive to lidocaine than WT channels (An et al., 
1996). The absolute insensitivity for the F1486del channel in the inactivated state 
to lidocaine indicates that the deficit in inactivation leads to the loss of response 
to lidocaine. Based on our findings, we predict that F1486 is crucial to the 
stabilization of the high-affinity lidocaine binding site in Nav1.5. This is surprising 
to us as the mutation of F1486 to Q did not alter the peak current dose-response 
curve of Nav1.5 for lidocaine (Balser et al., 1996). Therefore, for the first time, our 
mutagenesis study on sodium channel Nav1.5 reveals a critical role for F1486 on 
the potency and efficacy of lidocaine on cardiac sodium channels.  
D. Current-clamp studies on neonatal cardiomyocytes ectopically  
expressing recombinant F1486del channels 
We used neonatal rat ventricular cardiomyocytes as an expression system 
and studied the functional consequence of the mutant channel on cardiac action 
potential profile from a single cell aspect. Substantial prolongation of the action 
potential duration and the subsequent triggered EADs in these neonatal 
cardiomyocytes were observed. We also observed the late INa augmentation in 
cardiomyocytes. We hypothesized that in the patients the long-QTs is caused by 
the increase in late INa, which was induced by deletion of F1486. The increased in 
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late INa then led to the initiation of EADs, which are followed by the cardiac 
tachycardia.  
Taken together, the F1486del produces a loss-of-function alteration of 
sodium current density and gain-of-function alterations such as impairment of 
inactivation, augmentation of late sodium current, increase of ramp current, 
increase of window current. Although the peak current density is reduced by the 
deletion of F1486, our data indicate that the substantial gain-of-function changes 
induced by the F1486del appear to be sufficient to overcome this deficit and 
prolong the APD. The data we collected from our studies on lidocaine efficacy 
and potency test proved our idea that additional therapeutic interventions are 
required to overcome the relative insensitivity to lidocaine displayed by the 
F1486del mutant channel. Uncovering the effect of lidocaine on both WT and the 
F1486del mutant channels should provide a better understanding of role that a 
specific residue plays in mediating the sensitivity to a therapeutic reagent. Our 
study will further validate the concept that gene specific therapeutic drugs need 
to be developed and characterized to reverse the cardiac arrhythmia which is 
caused by different mutations in SCN5A.  
E. Trafficking and cellular localization of voltage-gated F1486del  
sodium channels  
In reality, the electrical excitability of excitable cells such as neurons and 
cardiomyocytes depends not only on the expression level of the voltage-gated 
sodium channels, but also upon their appropriate targeting to the plasma 
membrane. So far, several sodium channel mutations have been found to 
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underlie sodium channel trafficking defects, and these mutations were also 
shown to cause life-threatening cardiac arrhythmia. For example, in some 
Brugada syndrome cases, mutations have been described to reduce the surface 
expression since the channel cannot fold correctly and is retained with the 
cytoplasmic compartment ER (Valdivia et al., 2004). The sodium channel blocker 
lidocaine has been shown to be able to rescue the tsA 201 cells from attenuated 
Nav1.8 sodium current (Zhao et al., 2007). In addition, the application of 
pharmacological reagents aiming at blocking sodium channels can rescue the 
channel from trafficking defects. One example of this is the research performed 
by Priori’s group (Ruan et al., 2010). In their study, the application of the sodium 
channel blocker Mexiletine can facilitate the mutation protein targeting to the 
plasma membrane surface without changing the channel’s gating properties. 
Their study provided evidence that sodium channel trafficking can be modified by 
certain pharmacological Nav blockers. In my study, the cell surface sodium 
current density was decreased for F1486del mutant channel compared to WT 
hNav1.5 channel. Although the reasons for the low current density for the 
F1486del mutant channel are not known, one hypothesis is that this resulted 
from a channel trafficking defect that reduces the cell surface expression of 
functional channels. The low current densities for voltage-gated channels such 
as Nav1.5, Nav1.8, and HERG have been believed to be caused by trafficking 
defects (Okuse et al., 2002; Anderson et al., 2006; Ruan et al., 2010). There also 
exists the possibility that excessive activation of the sodium channel causes a 
toxic effect to the cells expressing the mutant F1486del protein. Thus, only those 
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cells expressing low level of the mutant protein can survive and were able to be 
investigated. To test these two hypotheses, there are a series of experiments that 
have been designed to find out the determinants of Nav1.5 F1486del channel 
expression in HEK293 cells. These future experiments will combine biochemistry, 
immunochemistry, and electrophysiology techniques.  
To test the hypothesis that F1486del can decrease the trafficking of 
sodium channels to the cell surface membrane, cell surface biotinylation 
experiment has been performed. The surface portion of the sodium channel 
protein was labeled with biotin and immunoprecipitated using streptavidin beads. 
Surface biotinylated protein was normalized to the β-tubulin protein. In my study, 
F1486del protein has a lower level of surface expression, which is consistent with 
the result from the patch-clamp study. However, this experimental strategy is not 
sufficient to rule out the possibility that the surviving cells express lower levels of 
F1486del mutant channels. Since the F1486del channel has a defect in the 
channel inactivation, which may cause secondary toxic effects to cells that 
express these channels. Additional experiments need to be performed further to 
test the hypothesis that cellular toxicity that is caused by the F1486del sodium 
channel.  
In order to test the hypothesis that cellular toxicity causes the decreased 
channel distribution at plasma membrane, I have designed a hNav1.5 cDNA 
construct bearing a cysteine to tyrosine mutation at amino acid 374 (C374Y). 
Previous studies indicated that this particular site is critical in determining the 
sensitivity to TTX (Leffler et al., 2005). TTX sensitive VGSCs such as Nav1.3, 
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Nav1.4, Nav1.6, and Nav1.7 carry a tyrosine residue at the corresponding site, 
which endows the channel with the property of being extremely sensitive to TTX 
(at nM level). 4-6 hours after transfection, cells will be replated onto 12 mm 
coversilps in a 24-well plate. At this step, 100 nM TTX will be added to the cell 
culture media and maintained in the culture media until starting the patch-clamp 
study. Since both WT and F1486del mutant channel carry this C374Y mutation, 
VGSCs will be inhibited in the presence of TTX. After washing out the residual 
TTX in the recording chamber, current densities will be compared to test the 
hypothesis that it is the cellular toxicity that causes the attenuated plasma 
membrane distribution of the sodium channel. The goal of this experiment is to 
test whether TTX can enhance the cell surface expression of the hNav1.5 
F1486del channel. If the surface fraction is augmented after incubating with TTX, 
then we can conclude that it is the over activation of the sodium channel that 
causes the cellular toxicity, which then leads to the overall decrease in the 
surface sodium channel protein.  
F. Summary and conclusions  
The overall results of my thesis are summarized as follows:  
1. Deletion of amino acid Phenylalanine (F) 1486 on Nav1.5 cause decrease in 
membrane current density. This is a sodium channel loss-of-function phenotype. 
The decrease in sodium current density happens not only in heterologous 
expression system of human embryonic kidney (HEK293) cells, but in native 
primary neonatal rat cardiomyocytes. This means the decrease in current density 
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is not the artifact caused by the difference in the expression system, but it 
indicates a phenotype caused by deletion of F1486 on Nav1.5.  
2. In both HEK293 cells and neonatal rat cardiomyocytes, deletion of F1486 
does not cause any change in cardiac sodium channel Nav1.5 activation profile. 
Both the voltage at which channel half-activated (V1/2) and the slope factor of 
activation were not affected by F1486del.  
3. In comparison to the activation profile, the inactivation of the sodium channel 
was disrupted by deletion of F1486 on Nav1.5. The disruption was presented as 
the positively shift of the V1/2 (voltage at which channel is half inactivated) in both 
HEk293 cells and neonatal cardiomyocytes. However, the slope factor was not 
significantly altered.  
4. hNav1.5 F1486del causes augmentation of late component of sodium current 
(late INa) in both HEK293 cells and cardiomyocytes.  
5. hNav1.5 F1486del enhanced window current.  
6. F1486del does not alter the time constants for channel deactivation. Again, 
the observations were seen in both HEK293 cells and cardiomyocytes.  
7. hNav1.5 F1486del channels cause significant prolongation of cardiac action 
potential duration (APD) in neonatal rat cardiomyocytes, and initiates 
spontaneous early afterdepolarizarions (EADs). The presence of EADs is a 
potential cause of QT interval prolongation, which underlines the occurrence of 
long-QT syndrome (LQTs). The EADs also can trigger the increase in cardiac 
automacity.  
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8. Lidocaine lost its pharmacological effect on hNav1.5 F1486del mutant 
channels. The reduced response was reflected by the increase of IC50 for 
lidocaine on the F1486del sodium channel in the resting state. In the inactivated 
state, F1486del sodium channel doesn’t respond to lidocaine in a dose-
dependent manner, which suggests amino acid F1486 can stabilize the sodium 
channel at a certain conformation that can facilitate lidocaine binding to the 
sodium channel. The poor pharmacological response of the F1486del mutant 
channel to antiarrhythmic drug lidocaine explains why the pediatric patient is 
refractory to lidocaine treatment.  
The results presented here reveal a relationship of hNav1.5 F1486del and 
the LQT syndrome found in the pediatric patient who had severe cardiac 
arrhythmia. The pharmacological studies on the mutant cardiac sodium channels 
reveals the causal relationship between the patient’s refractory response to 
lidocaine treatment and the linear structural changes induced by F1486del. 
Finally, the current thesis work demonstrates the cardiac functional changes in 
the single working cardiomyocyte level, meaning the changes in action potential 
duration and the occurrence of EADs. The work demonstrated here can explain 
why the patient has severe QT interval prolongation, and subsequent ventricular 
tachycardia. It will be important to elucidate the structural change that is induced 
by F1486del, and further identify potential pharmacological reagents that can 
inhibit the F1486del channels more efficaciously. Overall, the current study 
supports the idea of gene specific therapy, since alteration of one single amino 
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acid on hNav1.5 greatly alters the pharmacological response to certain 
antiarrhythmic drugs. 
G. Discussion on supplemental results: G1481E mutation increases  
window current and may lead to LQT3 in patients  
The initiation of the patch-clamp study on the G1481E sodium channel site 
mutation is based on the retrospective clinical case study by Tester et al. (Tester 
et al., 2005).Patients who carry this mutation were thought to be associated with 
LQT3 syndrome. In addition, as the F1486del site, the G1481E is also located in 
the intracellular loop III between transmembrane DIII and DIV. We did detailed 
biophysical studies on this mutant channel, and realized that unlike the F1486del 
channel, the G1481E mutant channel does not result in the shift of steady-state 
inactivation curve, which happens for most of the site mutations within the 
intracellular loop III (Bankston et al., 2007a; Bankston et al., 2007b; Ruan et al., 
2010). The G1481E mutation does not cause the statistical change in late 
sodium current either. However, the G1481E mutation does result in the 
depolarizing leftward shift in the steady-state activation, which will enhance the 
non-inactivating window current. Therefore, the overall increase in window 
sodium current could explain why the patients carrying this mutation present with 
LQT3. Detailed action potential studies on cardiomyocytes expressing the 
G1481E mutant channels will be necessary in the near future.  
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